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Background. Fatty acid esters of 17β-estradiol (E2) are a family of naturally
occurring, potent estrogens. Experimental data indicate that circulating E2 fatty
acid esters are synthesized and associate with lipoproteins, where they may
mediate antioxidant or endocrine effects. The aims of the present study were to
develop a method for quantitative determination of E2 fatty acid esters in human
serum, in lipoprotein fractions, and in ovarian follicular fluid; to determine
concentrations of serum E2 esters in pregnancy; and to investigate the effects of
postmenopausal estrogen therapy on the concentrations of serum E2 esters.
Methods. Lipoproteins were isolated from serum by sequential
ultracentrifugation. After isolation, saponification, and chromatographic
purification of the E2 ester fraction, the concentrations of hydrolyzed E2 fatty acid
esters in serum and in lipoproteins were determined by time-resolved
fluoroimmunoassay. In a randomized, placebo-controlled study, serum E2 ester
levels were determined in 26 postmenopausal women before and after 12 weeks
of oral (2 mg/d) or transdermal E2 (50 µg/d) or placebo treatment. Also, the effects
of high dose oral (2-4 mg/d) and transdermal estrogen therapy (50-100 µg/d) on
the levels of serum E2 fatty acid esters were compared in a crossover study in ten
postmenopausal women with histories of intrahepatic cholestasis of pregnancy, an
estrogen-related liver disorder, and in ten healthy postmenopausal women.
Results. In pregnancy, the median concentration of serum E2 fatty acid esters
was 70 pmol/l at 7-10 weeks of gestation and 470 pmol/l at 37-42 weeks of
gestation. The mean proportion of E2 esters to serum nonesterified E2 was 1.3% in
early and 0.5% in late pregnancy. The majority of serum E2 fatty acid esters (75%)
in pregnant women were recovered in the lipoprotein fraction. High density
lipoprotein was the principal carrier (54%) of lipoprotein-associated E2 fatty acid
esters in the blood, but the low density lipoprotein fraction also contained a
significant proportion, 28%, of the E2 esters. Ovarian follicular fluid had a high
mean concentration of esterified E2, 106 nmol/l, and the proportion of esterified
E2 to E2 ranged between 3% and 10%. Twelve weeks of oral E2 therapy
significantly increased the median concentrations of serum E2 fatty acid esters in
postmenopausal women, by 27%, from 77 pmol/l to 98 pmol/l. In contrast, neither
transdermal E2 nor placebo treatment had any effect on median serum E2 ester
levels. The change in the concentration of serum E2 esters, but not that of serum
E2, correlated positively with the changes in endothelium-dependent and -
independent vasodilatation during postmenopausal E2 therapy. Moreover, four
weeks of oral postmenopausal estrogen therapy increased the median level of
serum E2 fatty acid esters in twenty women by 29%, from 57 pmol/l to 73 pmol/l,
in association with increases in serum E2, estrone, and sex hormone-binding
globulin concentrations. During transdermal E2 treatment in the same subjects, the
median E2 ester level in the serum remained unchanged (53 pmol/l after treatment
vs. 57 pmol/l baseline). No statistically significant differences in the levels of
serum E2 esters were observed between women with a history of intrahepatic
cholestasis of pregnancy and healthy postmenopausal women.
Conclusions. A reproducible method was developed for the quantitative
determination of E2 fatty acid esters in human body fluids. The E2 ester values in
early pregnancy serum and follicular fluid were in line with previous studies. E2
esters represented a quantitatively minor estrogen metabolite in the serum during
pregnancy. Concentrations of serum E2 fatty acid esters correlated positively with
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serum E2 levels in both pregnant women and postmenopausal women during
estrogen treatment, and most of the circulating E2 fatty acid esters were associated
with high density and low density lipoproteins. These results are in agreement
with previous studies indicating the esterification of circulating E2 in high density
lipoproteins and the transfer of E2 esters to low density lipoproteins. In
postmenopausal women, the proportion of serum E2 esters to circulating E2 was
higher than in premenopausal or pregnant women. This might be attributed to
increased esterification of steroids during aging, as suggested previously, and also
to the potential role of E2 fatty acid esters as a storage form of estrogen. Oral, but
not transdermal E2 administration, increased serum levels of E2 fatty acid esters
statistically significantly in postmenopausal women. This might be attributed, at
least partly, to the higher dose of orally administered estrogen compared with
transdermal E2 treatment. Previous intrahepatic cholestasis of pregnancy did not
appear to affect the esterification of E2 during postmenopausal estrogen therapy. A
positive correlation between serum E2 ester levels and forearm blood flow
responses raises the possibility that E2 fatty acid esters may contribute to the
beneficial effects of oral estrogen therapy on vascular function.
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1. Introduction
The principal and the most potent estrogen in women is 17β-estradiol (E2). One of
the naturally occurring metabolites of E2 is its fatty acid ester derivative. These
lipophilic E2 metabolites have been identified as a family of long-chain fatty acid
esters (Hochberg 1998). E2 fatty acid esters are synthesized in various tissues,
including the blood, where, according to experimental studies, they are
transported almost exclusively in lipoprotein particles (Larner et al. 1987). On
account of their slow metabolism (Hershcopf et al. 1985), E2 fatty acid esters
induce more sustained estrogenic effects than the parent steroid E2 (Larner et al.
1985b). The biological role of E2 esters is not clear, but they may function as a
storage form of E2 in tissues and be hydrolyzed to active estrogen when needed
(Hochberg 1998). Also, E2 in its fatty acid esterified form appears to be a potent
antioxidant that might protect lipoproteins against oxidative modification
(Shwaery et al. 1997).
Only a few studies have determined endogenous E2 fatty acid ester levels in
human tissues. The highest concentrations of E2 esters have been reported in
ovarian follicular fluid (Larner et al. 1993), and in omental and subcutaneous
adipose tissue in both pre- and postmenopausal women (Larner et al. 1992b).
Circulating E2 ester levels appear to be lower than tissue E2 ester levels, as
determined in premenopausal women and in women undergoing ovarian
stimulation (Larner et al. 1992b).
In the present studies we describe a new method for the quantitative
determination of E2 fatty acid esters in human blood. With this method, we studied
the E2 fatty acid ester concentrations in pregnancy serum and lipoprotein fractions.
In further studies, we set out to investigate the effects of postmenopausal estrogen
therapy on serum E2 ester levels.
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2. Review of the literature
2.1. Estrogens
2.1.1. An overview of estrogen metabolism
In premenopausal women, estrogens are synthesized primarily in steroidogenic
tissues, which include the ovaries and, during pregnancy, the placenta. The major
estrogens secreted by the ovarian cells are estrone (E1) and E2. The principal
pathway of synthesis for estrogens in the ovarian follicle is shown in Figure 1.
Estrogens are either metabolized in peripheral tissues at the aromatic A ring,
yielding cathecol estrogens (2- and 4-hydroxy-E1), or hydroxylated at the carbon
16 position to form estriol (E3) (Figure 1). E3 is the most abundant estrogen in
urine. In plasma, the most abundant estrogen is E1 sulfate, derived from E1 and E2
by peripheral conversion. The plasma concentration of the most important
estrogen in premenopausal women, E2, is approximately 70-220 pmol/l in the
early and 1200-2600 pmol/l in the late follicular phase, and 700 pmol/l in the
luteal phase of the menstrual cycle (Carr 1998). In the plasma, E2 is transported
predominantly by albumin and sex hormone-binding globulin (SHBG) (Dunn et
al. 1981). A lesser proportion of the circulating E2 is not bound by proteins and
this free fraction is available for uptake by estrogen target tissues (Hammond
2002). In the target cells, estrogens bind to their receptors and the receptor-ligand
complex is translocated to the nucleus, where it regulates the expression of target
genes. Alternatively, estrogens may act through rapid non-transcriptional
mechanisms by modulating regulatory proteins located in the cell membrane or
the cytoplasm, especially in the vasculature (Simoncini et al. 2002).
During menopausal transition, the ovaries cease to secrete E2 and estrogens are
derived from aromatization of the androgens in tissues (Grodin et al. 1973). The
androgen precursors are secreted in part by the ovaries, which produce about 25%
of the circulating testosterone as well as significant proportions of the
androstenedione and dehydroepiandrosterone (DHEA) in postmenopausal women
(Brodie 1979; Simpson 2002). The adrenals mostly secrete DHEA sulfate and
DHEA, but also androstenedione (Simpson 2002). The production of these
steroids declines with advancing age (Labrie et al. 1997b). The conversion of
steroid precursors to active hormones takes place in the peripheral tissues,
including the mesenchymal cells of the adipose tissue, the osteoblasts and
chondrocytes of bone, the vascular endothelium and the smooth muscle cells as
well as the brain (Simpson 2002). DHEA must first be converted to
androstenedione, which in turn is aromatized to E1, the major circulating estrogen
in postmenopausal women. The aromatase activity in the tissues is regulated by
several factors, including the cytokines interleukin-6 and tumor necrosis factor α,
and prostaglandin E2 (Purohit and Reed 2002). E1 is reduced in the tissues to E2
by 17β-hydroxysteroid dehydrogenase enzymes (Labrie et al. 2000). In
postmenopausal women, the concentrations of estrogens are markedly higher in
the tissues than in the plasma (Pasqualini et al. 1996). The circulating estrogens
reflect the estrogen metabolism at the extragonadal sites, as active estrogens are
produced in the peripheral tissues after the menopause instead of being secreted
into the plasma by the ovaries (Labrie et al. 1997a).
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Figure 1. The principal pathways of estrogen biosynthesis and metabolism in
premenopausal women. 3β-HSD, 17β-HSD; 3β- and 17β-hydroxysteroid
dehydrogenases.
Pregnancy
Serum and urine concentrations of estrogens increase markedly during pregnancy
(Rado et al. 1970; Munson et al. 1970; Moutsatsou and Oakey 1986). The
placenta is mainly responsible for the production of large quantities of E1 and
particularly E3, which is the most abundant estrogen in pregnancy (Fishman et al.
1962). During the final months of human pregnancy, E3 is derived predominantly
from the placental conversion of DHEA sulfate of fetal adrenal origin (Siiteri and
MacDonald 1966). E1 and E2 are also synthesized from maternal steroid
precursors. Estrogens are released from the placenta into the maternal circulation
mainly in unconjugated form (Unnérus 1979). E3 is also excreted in the urine in
the unconjugated form, but a large proportion of the plasma estrogens is
metabolized in the liver to glucuronide and sulfate conjugates and excreted in the
bile. In the intestine, the principal E3 conjugate, E3 3-sulfate 16-glucuronide
(Adlercreutz et al. 1973) is hydrolyzed and further converted mainly to E3 16-
glucuronide and E3 3-glucuronide by intestinal bacteria and mucosal enzymes and
reabsorbed (Levitz et al. 1984). From the peripheral blood, E3 16-glucuronide re-
enters the enterohepatic circulation, while E3 3-glucuronide is excreted in the
urine (Tikkanen and Adlercreutz 1973).
Cholesterol
Cholesterol side chain
cleavage enzyme
Pregnenolone
17α -hydroxylase
17-hydroxypregnenolone
17,20-lyase
 Dehydroepiandrosterone OVARIAN FOLLICLE
(DHEA) 
3β-HSD
Androstenedione Testosterone
17β-HSD
Aromatase Aromatase
E1 sulfate Estrone (E1) 17β-Estradiol (E2)
17β-HSD
2-hydroxy-E1 16α-hydroxy-E1
2-methoxy-E1
Estriol (E3)
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Intrahepatic cholestasis of pregnancy
Intrahepatic cholestasis of pregnancy (ICP) usually starts in the third trimester of
pregnancy and is characterized by generalized pruritus. The diagnosis of ICP is
based on clinical findings as well as on increased serum bile acid levels and
aminotransferase activities, which return to normal soon after delivery (Germain
et al. 2002). The etiology of ICP is not known, but, in susceptible women, high
serum estrogen levels in late pregnancy are thought to play a role in the
development of the disorder (Tikkanen and Adlercreutz 1973). ICP more
commonly affects twin pregnancies with higher serum estrogen levels than single
pregnancies with lower levels of serum estrogens (Gonzalez et al. 1989).
Furthermore, ICP patients may develop symptoms or signs of cholestasis in the
nonpregnant state during the use of oral estrogens (Kreek et al. 1967b; Kreek et al.
1967a; Drill 1974; Reyes et al. 1981).
The metabolism of estrogens becomes altered in ICP patients, owing to
reduced excretion of steroid conjugates in the bile and, subsequently, to their
impaired enterohepatic circulation (Adlercreutz and Luukkainen 1967). Several
studies have indicated that ICP is not associated with a primary abnormality of
estrogen synthesis or metabolism (Adlercreutz et al. 1967; Tikkanen and
Adlercreutz 1973; Adlercreutz et al. 1974). Also, the serum levels of E2 and of
C19-steroids such as DHEA do not differ from those observed in normal
pregnancies (Germain et al. 1999; Sjövall and Sjövall 1970). There are, however,
reports of decreased maternal plasma levels of DHEA sulfate and downstream
estrogens (Leslie et al. 2000) as well as decreased cord plasma levels of steroid
sulfates of fetal origin (Laatikainen et al. 1974), which have suggested impairment
of the function of the fetoplacental unit in ICP.
ICP also includes alterations in progesterone metabolism (Reyes and Sjövall
2000). ICP patients have increased concentrations of sulfated steroid metabolites
in the serum and urine (Sjövall and Sjövall 1970; Laatikainen and Karjalainen
1973; Meng et al. 1997). It is not known, however, whether the changes in
progesterone metabolism in ICP are primary or secondary to cholestasis (Germain
et al. 2002).
2.1.2. Measurement of serum 17β-estradiol
Serum E2 concentrations can be measured by analytical methods of various types.
In immunoassays, antibodies are used for quantification of the antigen, E2.
Immunoassays for serum E2 can be performed directly, but water-soluble steroid
conjugates or steroid-binding proteins in the serum may interfere with the assay
(Leung et al. 1997; Thomas et al. 1987). Therefore, immunoassay procedures that
include extraction with organic solvents, or chromatographic steps to separate
cross-reacting compounds, are generally more reliable than direct assays of the
serum (Adlercreutz et al. 1981).
The first immunoassay was a radioimmunoassay (RIA) developed in the
1960’s for measurement of plasma insulin (Yalow and Berson 1960). RIAs are
still widely used as immunological assays for steroid hormones, but alternative
analytical methods using nonradioactive tracers, such as enzymes or fluorescent
compounds, have been developed (Hemmilä 1985). In the present work, we used
a commercial fluoroimmunoassay (FIA) method for the quantification of E2. This
method has shown a good correlation with a commercially available RIA method
(Sjöblom et al. 1990). The major advantages of FIAs, as compared with
conventional RIAs, are the use of nonradioactive reagents and increased reagent
stability, and the short counting time (Hemmilä et al. 1984).
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Fluoroimmunoassays
FIAs of small molecules such as E2 are usually competitive immunoassays, where
the fluorescent-labeled analyte competes with the unlabeled analyte in the sample
for binding to a specific antibody with a limited analyte binding capacity. In
separation assays, the fraction of the labeled analyte that is bound by the antibody
is separated from the excess of unbound labeled analyte, and analyzed with a
fluorometer. The concentration of the analyte in the sample is inversely correlated
with the amount of fluorescence detected. The factors that contribute to the
sensitivity of the assay include primarily the properties of the antiserum and the
optimization of the assay, the separation of the bound from the free analyte (the
degree of nonspecific binding), and experimental errors, as well as the accuracy of
the fluorescence measurement (the amount of background fluorescence). In time-
resolved FIA (TR-FIA), the fluorescence emitted by the label (fluorophore) is
measured after an adequate delay to avoid interference by the background
fluorescence of the sample and by scattered excitation light (Hemmilä 1988).
Lanthanide metals such as europium (E3+) chelates are typically used as
fluorophores in TR-FIAs (dissociation enhanced lanthanide fluoroimmunoassay,
DELFIA®).
2.2. Fatty acid esters of estrogens and other steroids
2.2.1. General
Nonpolar derivatives of pregnenolone were discovered over 20 years ago as a new
class of naturally occurring steroid metabolites (Hochberg et al. 1977). Since then,
most steroids have been shown to form esters with predominantly long-chain fatty
acids. These include other ∆5-3β-hydroxysteroids, estrogens, testosterone,
corticoids, and also ecdysteroids in insects (Hochberg 1998). Adrenal steroids are
esterified at carbon 3 of the A ring, similarly to cholesterol fatty acid esters,
estrogens at carbon 17 or carbon 16 in the D ring (Figure 2), and corticoids at
carbon 21. The rate of synthesis and the fatty acid composition of the steroid
esters vary markedly from tissue to tissue (Pahuja and Hochberg 1989). The major
difference between the steroid fatty acid esters and other steroid conjugates is that
fatty acid esterification renders the steroid molecule very lipophilic. Previous
studies have focused mainly on the metabolism of fatty acid esters of sex
hormones, as well as those of the steroid hormone precursors, ∆5-3β-
hydroxysteroids.
2.2.2. Synthesis of 17β-estradiol fatty acid esters
Synthesis of 17β-estradiol  fatty acid esters in tissues
A variety of steroidogenic and other tissues, including breast tumors and breast
cancer cell lines, are capable of synthesizing E2 fatty acid esters (Schatz and
Hochberg 1981; Abul-Hajj 1982; Adams et al. 1986; Katz et al. 1991). The
highest rates of synthesis in the rat have been detected in the spleen, lungs, and
uterus, whereas the liver and adipose tissue synthesize far less of the lipophilic E2
derivatives (Schatz and Hochberg 1981; Pahuja and Hochberg 1989). Human
omental fatty tissue, however, appears to have a higher rate of E2 ester synthesis
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than that described in rat adipose tissue (Kanji et al. 1999). E2 esters are formed
by direct esterification of the parent steroid E2 (Larner et al. 1992a). In tissues, the
esterification reaction is catalyzed by an acyl coenzyme A:cholesterol
acyltransferase (ACAT) (Martyn et al. 1987; Paris and Rao 1989). However, this
is apparently not the same as the ACAT that esterifies cholesterol, for the
composition of biosynthetic E2 fatty acid esters is not similar to that of the
endogenous cholesterol esters in the bovine uterus (Mellon-Nussbaum et al. 1982)
and because esterification of E2 in the rat liver microsomes cannot be inhibited by
the same ACAT inhibitor that inhibits the formation of cholesterol esters (Pahuja
and Hochberg 1995). Moreover, the difference in fatty acid composition between
the E2 and the corticosterone esters in the same tissue suggests that they might be
formed through different enzymatic processes (Pahuja and Hochberg 1989).
Recent studies indicate that clofibrate treatment may enhance the esterification of
E2 and some other steroids in rat liver microsomes (Xu et al. 2001a; Xu et al.
2001b; Xu et al. 2001c; Xu et al. 2002).
Figure 2. 17β-Estradiol 17-stearate. The aromatic A ring has an intact hydroxyl
group at carbon 3, while the 17β-hydroxyl in the D ring is esterified with a long-
chain fatty acid.
E2 fatty acid esters are a heterogeneous family of predominantly long-chain
fatty acid esters at carbon 17 (Figure 2) (Mellon-Nussbaum et al. 1982; Martyn et
al. 1988). The fatty acid composition of biosynthetic E2 esters varies substantially
from tissue to tissue (Pahuja and Hochberg 1989; Paris and Rao 1989), but they
consist mainly of unsaturated fatty acid esters such as arachidonate, oleate, and
linoleate, as described in bovine endometrial tissue (Mellon-Nussbaum et al.
1982), bovine placenta (Martyn et al. 1988), and calf hepatic and adrenal
microsomes (Paris and Rao 1989). In contrast, the major components of the E2
fatty acid esters synthesized in human breast tumors were the saturated esters E2
17-palmitate and 17-stearate (Larner et al. 1985a; Pahuja and Hochberg 1995).
Synthesis and transport  of 17β-estradiol  fatty acid esters in blood
E2 is also esterified in plasma, although at a lower rate than in many other tissues.
In blood and in ovarian follicular fluid, E2 fatty acid esters are synthesized by
lecithin:cholesterol acyl transferase (LCAT), the same enzyme that esterifies
cholesterol (Pahuja and Hochberg 1995; Pahuja et al. 1995; Höckerstedt et al.
2002). The fatty acid composition of biosynthetic E2 fatty acid esters in plasma is
similar to that of the endogenous and biosynthetic cholesterol esters (Pahuja and
Hochberg 1995). Furthermore, the E2 esterification reaction may be enhanced by
adding purified human LCAT and inhibited by a LCAT inhibitor,
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dithionitrobenzoic acid (DTNB) (Höckerstedt et al. 2002). E2 in the blood is
esterified solely at carbon 17, in contrast to cholesterol and adrenal steroids,
which are esterified in the blood at carbon 3 by LCAT (Kanji et al. 1999). Also,
the rate of esterification of E2 in the blood and in the follicular fluid is much lower
than in these other steroids esterified by LCAT (Jones and James 1985; Roy and
Bélanger 1989a; Pahuja and Hochberg 1995). This might be attributed to the
location of the 17β-hydroxyl of E2, which is sterically hindered by the adjacent
methyl group at carbon 13 (Figure 2) (Kanji et al. 1999).
The esterification of E2 in the blood and the follicular fluid takes place in high
density lipoprotein (HDL) particles (Leszczynski and Schafer 1991; Höckerstedt
et al. 2002). From the HDL3 particles in which they are synthesized, E2 fatty acid
esters may be transferred to low density lipoprotein (LDL) particles, a process
which is suggested to be at least partly mediated by the cholesterol ester transfer
protein (CETP) (Helisten et al. 2001). Experimental studies have shown that E2
fatty acid esters are associated predominantly with lipoproteins in the blood
(Larner et al. 1987). In contrast to nonesterified E2 and many estrogen metabolites,
E2 fatty acid esters are not bound by albumin or SHBG to any significant extent
(Larner et al. 1987).
2.2.3. Metabolism of 17β-estradiol fatty acid esters
Biosynthetic studies indicate that neither the fatty acid esters of E2 nor those of
other steroids are secreted from tissues. Being very lipophilic substances, they
rather are retained in the cells where they were formed (Schatz and Hochberg
1981; Adams et al. 1986; Poulin et al. 1989). E2 fatty acid esters do not bind to
estrogen receptors, as studied in rabbit uterine tissue (Janocko et al. 1984), but
their binding to the more recently described estrogen receptor β isoforms has not
been specifically investigated. Metabolic studies support the concept that, to exert
estrogenic effects, E2 fatty acid esters require to be hydrolyzed to E2 (Larner et al.
1985b). An esterase that cleaves E2 17-esters has been isolated from human breast
cyst fluid (Banerjee et al. 1991). Cell culture studies have demonstrated that
intracellular esterases generate E2 from exogenous E2 fatty acid esters, which
leads to an estrogenic response in the cells (Katz et al. 1991).
According to metabolic studies in rats and in human subjects, the plasma half-
life of long-chain fatty acid esters of E2 is significantly longer than that of the
parent steroid E2 (Larner and Hochberg 1985; Hershcopf et al. 1985).
Furthermore, the metabolism of intravenously injected E2 fatty acid esters is
remarkably slower and more complete than that of E2, which is rapidly oxidized in
the blood (Hershcopf et al. 1985). This retarded metabolism of E2 17-esters is
attributed to the slow hydrolysis of the esters prior to the rapid oxidation of the
parent steroid E2 at the 17 position. Unsaturated esters may be metabolized faster
than saturated ones (Hershcopf et al. 1985). The rate of metabolism of E2 esters is
inversely correlated to the fatty acid chain length, but it appears that the longer
chain E2 esters are cleared more rapidly from blood than the smaller esters. This
suggests that long-chain fatty acid esters of E2 are removed from the circulation,
followed by subsequent hydrolysis and oxidation in the tissues (Hershcopf et al.
1985).
Studies of animals indicate that E2 fatty acid esters may accumulate in various
tissues during estrogen administration. When high doses of E2 were administered
to ovariectomized rats via subcutaneous silastic implants for one week, markedly
increased levels of E2 fatty acid esters were detected in the lungs, uterus, and
spleen, that is in the tissues where the rate of E2 ester synthesis had previously
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been found to be high (Hochberg et al. 1991). Adipose tissue, which in previous
studies had had a low rate of E2 ester synthesis, also contained high levels of E2
esters. In rat serum and liver, the E2 fatty acid ester concentrations remained low
during subcutaneous E2 administration. Others have shown that E2 injections into a
male calf induced retention of fatty acid esterified E2 in perirenal fat (Paris et al.
1994). Consistently, a recent study demonstrated that lipophilic E2 esters
accumulate in bovine adipose tissue during treatment of the animals with estrogen
implants in order to promote growth (Maume et al. 2001).
2.2.4. Biological effects of 17β-estradiol fatty acid
esters
Several studies have shown that E2 fatty acid esters, consistent with their slow
metabolism, exert powerful and long-acting estrogenic effects. When
administered either intravenously or subcutaneously to immature female rats, E2
17-stearate induced a slow-onset uterotrophic effect that lasted twice as long as
that of E2 (Larner et al. 1985b). Prolonged estrogenic effects of E2 17-stearate
were also demonstrated in other estrogen target tissues of the rat: the liver, brain,
and pituitary gland (MacLusky et al. 1989). This was attributed to the delayed
onset as well as the increased duration of the estrogenic signal after administration
of E2 17-stearate, as compared with E2. A sustained uterotrophic effect was also
demonstrated in rats treated with single subcutaneous injections of E2 3,17-
dipalmitate and -dioleate (Vázquez-Alcántara et al. 1985; Vázquez-Alcántara et
al. 1989). In addition to parenteral administration, oral E2 17-stearate treatment
was also more potent compared with oral E2, as measured by uterine and vaginal
effects in juvenile rats (Paris et al. 2001). Inconsistently with these previous
studies, a recent study did not find any difference in the uterotrophic effects of E2
17-stearate and E2 in ovariectomized rats (Mills et al. 2001). In contrast, chronic
continuous E2 17-stearate treatment with a subcutaneous pump induced a strong
mitogenic effect on rat mammary tissue, which was not observed during treatment
with E2.
Thus, E2 fatty acid esters with different routes of administration and at different
dosages have almost invariably shown stronger and more sustained estrogenic
effects as compared with E2. This may be attributed to the protection of the steroid
nucleus from metabolism by fatty acid esterification (Larner and Hochberg 1985)
and potentially also to the accumulation of these derivatives in fatty tissues, where
they slowly release E2. The biological role of E2 fatty acid esters is not
understood, but it has been suggested that, as long-lived hormones, they might
provide target tissue stimulation when estrogen levels in the circulation are low
(Hochberg 1998).
2.2.5. Endogenous 17β-estradiol fatty acid esters in
humans
Human endogenous E2 fatty acid esters were first described in blood by Janocko
and Hochberg (1983), who found that human female serum contained lipophilic
E2 derivatives which, upon alkaline hydrolysis, released E2, which could be
detected by RIA. In further studies, the presence of lipophilic E2 ester derivatives
in human male and female serum was confirmed by a radiochemical isotope
dilution technique (Janocko and Hochberg 1986). However, only a small number
of subjects were studied. Also, the E2 ester determinations in these studies were
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not quantitative and so could not be compared with serum nonesterified E2 levels.
A new method was developed by the same group, based on chromatographic
purification of the E2 fatty acid ester fraction, and following saponification,
analysis of hydrolyzed E2 esters by gas chromatography-mass spectrometry (GC-
MS) (Larner et al. 1992b). Several human tissues were analyzed for endogenous
E2 esters. The highest concentrations of E2 fatty acid esters were detected in
subcutaneous and omental adipose tissue with an average concentration of 960
fmol/g in premenopausal women, and an unexpectedly high level, 400 fmol/g, in
women who had been menopausal for at least 15 years and had very low serum
levels of nonesterified E2. E2 esters were also detected in breast cyst fluid and, in
smaller quantities, in muscle. Urine did not contain any measurable amounts of
esterified E2, in agreement with the previous biosynthetic studies, which had
indicated that E2 esters were not secretory products (Schatz and Hochberg 1981).
The mean circulating levels of E2 esters in premenopausal women (n=4) were
lower than expected, ranging between 7 and 22 pmol/l, or 2% to 22% of serum
nonesterified E2 levels. In women receiving gonadotrophin treatment for
infertility, however, higher serum E2 ester concentrations were detected, 48 to 92
pmol/l (n=3). The serum E2 ester levels measured in both men and
postmenopausal women were regarded as not detectable. The value measured in
male serum was subtracted as a blank from the female serum values.
The studies described above proved that E2 fatty acid esters exist
endogenously, but the composition of these derivatives was not yet clear. As
ovarian follicular fluid contained very high concentrations, approximately 100
nmol/l of esterified E2, the composition of human endogenous E2 fatty acid esters
could be characterized by high performance liquid chromatography (HPLC) and
MS of the intact esters (Larner et al. 1993). The most abundant ester of E2 was
linoleate (43%); the others were palmitate (20%), arachidonate (19%), oleate
(14%), and stearate (4%), all at carbon 17 of the molecule.
2.2.6. Fatty acid esters of other steroids
Estriol
The most polar of the main estrogens, E3, may also become esterified with fatty
acids. However, the endogenous concentrations of E3 fatty acid esters have not
been investigated in humans or in any other species. E3 is a poorer substrate than
E2 for esterifying enzymes, as it is esterified at a lower rate than E2 both in tissues
and in plasma (Poulin et al. 1990; Pahuja et al. 1991; Shwaery et al. 1998; Kanji
et al. 1999). In human blood, E3 is preferentially esterified by LCAT at 17β (80%)
compared with the 16α-hydroxyl (20%) (Kanji et al. 1999). In  human adipose and
placental tissue, as well as in rat lung, both D ring hydroxyls of E3 may be
converted to fatty acid esters, but with a slight preference for carbon 16 esters
(Pahuja et al. 1991; Kanji et al. 1999). The fatty acid composition of E3 esters
resembles that of E2 esters (Pahuja et al. 1991). Like E2 esters, fatty acid esters of
E3 do not bind to the estrogen receptor, but studies in ovariectomized mice
indicate that they too are potent estrogens (Zielinski et al. 1991).
Estrone
In contrast to E2 and E3, several studies suggest that E1 is not converted to fatty
acid esters either in tissues like rat mammary tumors (Schatz, 1981) and rat
hepatic microsomes (Xu et al. 2002) or in human plasma (Jones and James 1985;
Shwaery et al. 1998). Although E1, a very nonpolar estrogen, is associated with
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lipoproteins in vitro (Leszczynski and Schafer 1990; Leszczynski and Schafer
1991; Shwaery et al. 1998), LCAT in HDL does not appear to have esterifying
activity towards E1, which has a ketone group at carbon 17 and only one hydroxyl
group in the aromatic A ring. There is, however, a conflicting report of extensive
acylation of E1 in rat lipoproteins (Virgili et al. 1999). The same group has
measured very high plasma concentrations (200 nmol/l to 500 nmol/l) of nonpolar
E1 metabolites in both men and women (Ardévol et al. 1997; Fernández-Real et al.
1999). These reported plasma levels seem unphysiologically high, and they have
not been confirmed by any other laboratory.
Testosterone
Like E2, endogenous testosterone fatty acid esters are found mainly in fatty
tissues, as described in male rats (Borg et al. 1995). Most tissues from male rats,
including blood, liver, and brain, did not contain any detectable amounts of
esterified testosterone (Borg et al. 1995), although biosynthetic esterification of
testosterone has been described in the brain (Kishimoto 1973). Lipophilic
testosterone metabolites have also been detected in tissues from mud snails
(Gooding and LeBlanc 2001).
In men, two studies have reported relatively high levels of a saponifiable
metabolite of testosterone in the serum (Addo et al. 1989; Addo et al. 1990).
These studies are not in agreement with other reports showing that testosterone is
not esterified in human blood (Jones and James 1985; Roy and Bélanger 1989a;
Kanji et al. 1999). Furthermore, because there is evidence that steroid fatty acid
esters are not secretory products, the presence of testosterone esters in human
blood needs further confirmation (Borg et al. 1995).
∆5-3β-hydroxysteroids
The steroid hormone precursors pregnenolone and DHEA are extensively
converted to fatty acid ester derivatives in many tissues. Pregnenolone fatty acid
esters may be converted to fatty acid esters of 17-hydroxypregnenolone and
DHEA in the adrenal (Mellon-Nussbaum et al. 1980), but this pathway is not
likely to be physiologically relevant (Hochberg 1998). A high rate of conversion
of pregnenolone, DHEA, and androstene-3β,17β-diol to their unsaturated fatty
acid esters has been described in the rat brain (Vourc'h et al. 1992; Smith and
Watson 1997). Others have shown that fatty acid esterified C19-steroids represent
the major form of intracellular steroids in ZR-75-1 breast cancer cells (Poulin et
al. 1989; Poulin et al. 1990). Endogenous fatty acid esters of pregnenolone, 17-
hydroxypregnenolone, and DHEA have been identified and quantified in bovine
adrenals and corpora lutea (Hochberg et al. 1977; Hochberg et al. 1979; Albert et
al. 1980). Also, endogenous concentrations of pregnenolone, DHEA, and
androstene-3β,17β-diol esters have been determined in adrenal tissue in the dog,
the rat, and the guinea pig as well as in humans (Bélanger et al. 1990). Like E2
fatty acid esters, pregnenolone esters produced in the adrenal are a mixture of
fatty acid esters (Mellon-Nussbaum et al. 1979). Unsaturated fatty acid esters of
androsterone have been detected in human breast cyst fluid (Raju et al. 1981; Raju
et al. 1985).
In blood and ovarian follicular fluid, pregnenolone, DHEA, and androstene-
3β,17β-diol are esterified by HDL3-associated LCAT, similarly to the estrogens E2
and E3 (Leszczynski et al. 1989; Leszczynski and Schafer 1990; Leszczynski and
Schafer 1991; Lavallée et al. 1996a). Of these steroids, pregnenolone is the one
most actively converted into fatty acid ester derivatives by LCAT, followed by
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DHEA and androstene-3β,17β-diol (Jones and James 1985; Roy and Bélanger
1989a; Leszczynski and Schafer 1991; Lavallée et al. 1996a). The composition of
biosynthetic fatty acid esters of pregnenolone and DHEA in blood is similar to the
native cholesterol esters (Leszczynski and Schafer 1991; Lavallée et al. 1996a).
Both biosynthetic and endogenous DHEA and pregnenolone fatty acid esters
associate almost exclusively with lipoproteins of blood in humans and in several
other species (Roy and Bélanger 1989c; Bélanger et al. 1992; Roy and Bélanger
1993; Lavallée et al. 1996b). They may be transferred from HDL to very low
density lipoprotein (VLDL) and LDL fractions, a transfer which is probably not
mediated by CETP (Leszczynski et al. 1989; Provost et al. 1997).
The fatty acid esters of both DHEA and pregnenolone circulate in human blood
at nanomolar concentrations. In men, the concentration of DHEA esters in blood
is about half of that of the parent steroid (Roy and Bélanger 1993). In contrast,
pregnenolone fatty acid ester levels in human plasma are about twice as high as
the nonesterified pregnenolone levels (Bélanger et al. 1990; Roy and Bélanger
1992). Increased plasma levels of nonpolar derivatives of DHEA and
pregnenolone have been reported in patients with hirsutism and acne, and also in
postmenopausal women with breast cancer (Jones and James 1985). During aging,
DHEA and pregnenolone fatty acid ester levels in the serum decline markedly in
both men and women (Bélanger et al. 1994; Jones and James 1985). However, the
ratio of DHEA fatty acid esters to DHEA appears to increase with age (Bélanger
et al. 1994). Concentrations of serum DHEA fatty acid esters may be increased in
elderly men and women by percutaneous DHEA treatment (Labrie et al. 1997a).
There is evidence that insulin may stimulate fatty acid esterification of DHEA in
serum (Lavallée et al. 1997).
Human follicular fluid contains twice as much esterified pregnenolone as the
free steroid (Roy and Bélanger 1989b). Pregnenolone esters in follicular fluid are
primarily unsaturated fatty acid esters, such as oleate and linoleate (Roy and
Bélanger 1989b).
Although substantial amounts of esterified DHEA and pregnenolone circulate
in human blood, their concentrations relative to serum cholesterol are low. It has
been estimated that one in a thousand HDL particles contains an esterified steroid
hormone molecule (Leszczynski and Schafer 1991). Lipoprotein-associated
steroid fatty acid esters are, however, suggested to play an important role in
peripheral steroidogenesis. LDL-incorporated fatty acid esters of DHEA and
pregnenolone have been shown to be cleared relatively rapidly from the
circulation (Bélanger et al. 1992), suggesting that they might be taken up by
tissues via lipoprotein receptors. This is supported by data on ZR-75-1 breast
cancer cells, which can internalize LDL-incorporated DHEA and androstene-
3β,17β-diol fatty acid esters and further convert DHEA fatty acid esters to DHEA
and androstene-3β,17β-diol (Roy and Bélanger 1993). Moreover, pregnenolone
fatty acid esters incorporated in LDL and HDL may serve as substrates for
progestin synthesis in ovarian granulosa cells (Roy and Bélanger 1991; Roy and
Bélanger 1992). Also, bovine and guinea pig adrenocortical cells can convert
HDL- and LDL-associated pregnenolone fatty acid esters into unconjugated
steroids (Provencher et al. 1992). These data indicate that fatty acid esters of
steroid hormone precursors transported by lipoproteins may be converted to
biologically active hormones in peripheral cells without de novo steroidogenesis.
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2.3. Postmenopausal estrogen therapy
To treat postmenopausal symptoms, various preparations of estrogen, usually in
combination with progestins, may be administered either orally, transdermally by
patches, as a percutaneous gel, by subdermal pellets, or vaginally. The estrogens
most commonly used are E2, E2 valerate, and conjugated equine estrogens, which
consist mainly of E1 sulfate. These preparations differ from each other in respect
of metabolism and hepatobiliary effects.
2.3.1. Pharmacokinetics of oral and transdermal
estrogen
Orally administered E2 undergoes extensive metabolism mainly to E1 and E1
sulfate by the intestinal bacteria and mucosa as well as the liver before entering
the systemic circulation (Ryan and Engel 1953; Longcope et al. 1985; de Ziegler
1991). Therefore, to obtain similar E2 levels in peripheral blood compared with
transdermal estrogen administration, much higher doses of estrogen have to be
administered via the oral route. Thus, during oral estrogen treatment, the liver is
exposed to high estrogen concentrations in the portal blood. This is reflected by
elevated concentrations of estrogen metabolites in both plasma and urine during
oral as compared with transdermal E2 treatment (Mueck et al. 2002), since the
liver is mainly responsible for the metabolism of estrogens (Song et al. 1969).
The plasma level kinetics of E2, E1, and their conjugates is similar for orally
administered E2 and E2 valerate (Nichols et al. 1984; Düsterberg et al. 1985;
Zimmermann et al. 1998). Oral E2 administration causes serum E2 levels to peak
after approximately six hours (Dada et al. 1978; Powers et al. 1985). Serum
estrogen levels fluctuate more during oral E2 treatment than the more stable
plasma estrogen levels achieved during transdermal E2 treatment (Jewelewicz
1997). During transdermal E2 therapy with patches changed twice weekly,
therapeutic serum E2 levels are achieved in approximately four hours, and they
gradually decline to lower values which are maintained over the period of use
(Powers et al. 1985; Stanczyk et al. 1988; Scott et al. 1991; Sitruk-Ware 1993).
Serum estrogen concentrations return to the pretreatment levels within 24-48
hours after removal of the patch (Powers et al. 1985). In comparison with twice
weekly transdermal systems, 7-day patches delivering E2 50-100 µg/d have shown
comparable serum E2 levels with smaller fluctuations between peak serum E2 and
minimum values (Gordon 1995), and, during E2 administration by subdermal
pellets, serum E2 values remain even more constant (Stanczyk et al. 1988).
Similar serum E2 values, close to premenopausal early follicular phase levels,
are obtained by transdermal E2 50-100 µg/d and oral E2 treatment 1-2 mg/d
(Crook 1997). Oral administration of E2 2 mg/d causes higher plasma E2 levels
than 50 µg/d of transdermal E2 administration (Powers et al. 1985; Scott et al.
1991; Geisler et al. 1999). In smokers, the serum estrogen levels reached by oral
E2 therapy are lower than in non-smokers, as smoking enhances the hepatic first
pass metabolism of E2 and stimulates the 2-hydroxylation metabolic pathway of
estrogens (Geisler et al. 1999).
Short-term oral E2 treatment already induces marked increases of 10 to 20-fold
in serum E1 levels (Yen et al. 1975; Lyrenäs et al. 1981; Holst 1983; Powers et al.
1985; De Lignieres et al. 1986). Similarly, serum E1 sulfate levels increase 20 to
50-fold (Dada et al. 1978). During long-term oral estrogen treatment, these
elevations are even more marked and sustained (Slater et al. 2001), in contrast to
transdermal E2 administration, during which the serum E2/E1 ratio is close to one,
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at the physiological, premenopausal level (Chetkowski et al. 1986; Powers et al.
1985; Padwick et al. 1985). Serum E1 levels are only approximately doubled by
transdermal E2 treatment (Chetkowski et al. 1986; Steingold et al. 1985; Powers et
al. 1985). Thus, oral E2 treatment induces accumulation of estrogen metabolites,
the implications of which are not understood (Slater et al. 2001).
Neither oral nor transdermal estrogen treatment at the usual dosages reduces
plasma gonadotrophins to premenopausal levels (De Lignieres et al. 1986;
Steingold et al. 1985; Powers et al. 1985; Chetkowski et al. 1986), but these
effects appear to be similar by the two routes of administration with the usual
dosages of postmenopausal estrogen.
2.3.2. Hepatobiliary effects
The effects of estrogens on the liver depend not only on the route of
administration but also on the estrogen dose used and the duration of liver
exposure to the estrogens. As all estrogens enter the liver more readily than other
organs, the liver is the primary site at which the pharmacological effects of
estrogens are manifested (Judd 1987). Also, different types of estrogen are
metabolized by the liver at varying rates, and those with a reduced metabolism,
like ethinyl E2, exert more powerful effects on the liver (Campbell and Whitehead
1981; de Ziegler 1991).
In response to oral estrogen administration, the liver increases its synthesis of a
number of proteins, such as renin substrate, SHBG, corticosteroid- and thyroxine-
binding globulin, transferrin, ceruloplasmin, apolipoproteins A and B, and several
coagulation and fibrinolysis factors (de Ziegler 1991; Corson 1993). The effect of
oral estrogens on the synthesis of several of these proteins is dose-related (Geola
et al. 1980; Chetkowski et al. 1986). The serum SHBG level appears to be the
most sensitive marker of estrogen action on the liver (Geola et al. 1980; de Ziegler
1991). However, the metabolic effects of increased levels of serum steroid-
binding proteins are not clear. Despite elevating the serum renin substrate level,
the usual doses of oral estrogen do not appear to increase the risk of hypertension
in postmenopausal women (de Ziegler 1991; The Writing Group for the PEPI
Trial 1995; Pripp et al. 1999; Seed et al. 2000). Different orally administered
types of estrogen also increase the serum levels of C-reactive protein (Vehkavaara
et al. 2001; Skouby et al. 2002) which may be of clinical significance (Ridker
2003). However, oral estrogen therapy decreases the serum levels of several other
inflammation markers, such as cell adhesion molecules, interleukines -1β and -6,
and tumor necrosis factor α or leaves them unchanged (Zanger et al. 2000;
Vongpatanasin et al. 2003), suggesting that oral estrogen therapy is not associated
with increased vascular inflammation (Silvestri et al. 2003). Liver function, as
measured by serum albumin or bilirubin levels, alkaline phosphatase or the
activities of several other hepatic enzymes, is not modulated by oral E2
administration (Mueller and Kappas 1964; Moore et al. 1987). However, very
high doses of E2 (5 to 200 mg/d) impair the hepatic excretory capacity of the
sulfobromophthalein dye (Mueller and Kappas 1964).
Oral estrogen increases the cholesterol content of the bile. The biliary
cholesterol saturation index has been shown to increase in association with serum
E1 levels during oral E2 valerate administration (van Erpecum et al. 1991). Several
studies have demonstrated an increased risk of cholecystitis among
postmenopausal estrogen therapy users (Nelson et al. 2002).
In contrast to oral estrogen administration, transdermal estrogen avoids the
hepatic first pass metabolism and thus, does not, at the usual dosages, exert
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hepatic effects as measured by serum SHBG, C-reactive protein, or renin substrate
levels or coagulation parameters (Chetkowski et al. 1986; Steingold et al. 1991;
Campagnoli et al. 1993; Vehkavaara et al. 2001).
2.3.3. Effect of estrogen therapy on serum lipid levels
After the menopause, the levels of serum LDL cholesterol rise and those of HDL
cholesterol may decrease (Stevenson et al. 1993). Postmenopausal estrogen
therapy with oral E2 or E2 valerate induces favorable effects on serum lipoprotein
levels by significantly reducing serum total and LDL cholesterol as well as
lipoprotein (a) and increasing serum HDL cholesterol concentrations (Tikkanen et
al. 1978; Godsland 2001). The lower dose of oral E2 of 1 mg/d induces smaller
effects on total, HDL, and LDL cholesterol compared with the 2 mg/d dose
(Godsland 2001). The decrease in LDL cholesterol during oral estrogen treatment
is due to the increased rate of LDL catabolism (Walsh et al. 1991) caused by
increased amounts of hepatic LDL receptors (Windler et al. 1980). Oral estrogen
increases HDL cholesterol levels by increasing the production of apolipoprotein
A-I (Walsh et al. 1994). Transdermal E2 administration also increases HDL
cholesterol and reduces LDL and total cholesterol and lipoprotein (a) levels, but to
a lesser extent than oral estrogens (Godsland 2001). The duration of E2 treatment
appears to be important for the impact of transdermal E2 administration on serum
lipid values (Stanczyk et al. 1988; Ory et al. 1998). Oral estrogen therapy
increases the production and the catabolism of VLDL, leading to elevated levels
of serum triglycerides (Campos et al. 1997). In contrast to oral E2, transdermal E2
treatment lowers serum triglycerides towards the levels seen before menopause
(Godsland 2001).
A combination of oral or transdermal E2 therapy with progestin, either
continuous or cyclic, influences the effects of estrogen on HDL cholesterol and
triglyceride levels (Godsland 2001). These effects depend on the type and dose of
progestin added (Tikkanen 1999; Shulman 2002).
2.3.4. Cardiovascular effects
Apart from the effects on serum lipids, there is evidence that estrogen replacement
therapy exerts beneficial effects on the cardiovascular system by reducing
oxidative stress and enhancing endothelial function (Ganz 2002). In numerous
studies, chronic administration of estrogen to postmenopausal women has
significantly improved endothelial function (Vita and Keaney 2001). A recent
study has suggested that E2 associated with HDL induces vasodilatation following
HDL binding to its receptor in endothelial cells (Gong et al. 2003). Furthermore,
E2 acts as a potent antioxidant in vitro and is able to protect LDL from oxidative
modification (Mazière et al. 1991; Rifici and Khachadurian 1992; Arteaga et al.
2000), even at physiological E2 concentrations (Shwaery et al. 1997; Hwang et al.
2000). Postmenopausal estrogen treatment with oral conjugated equine estrogens
has been shown in several studies to inhibit the oxidation of LDL (Wilcox et al.
1997; Özden et al. 2001) and HDL in vitro (Wakatsuki et al. 1998). E2 valerate
treatment decreased the plasma level of antibodies against oxidized LDL
(Hoogerbrugge et al. 1998). Transdermal E2 therapy of 50 to 100 µg/d has also
decreased the susceptibility of LDL to oxidative modification in several studies
(Sack et al. 1994; Koh et al. 1997; Wakatsuki et al. 2002). However, not all
studies have supported the protection of lipoproteins against oxidation by
postmenopausal estrogen therapy (Brussaard et al. 1997; McManus et al. 1997;
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Abbey et al. 1999; Hermenegildo et al. 2001). Moreover, estrogen therapy
combined with progestins does not appear to decrease LDL susceptibility to
oxidation (Nenseter et al. 1996; Wen et al. 1999; Bureau et al. 2002).
In contrast to the above discussed beneficial effects on several cardiovascular
risk factors, and epidemiological data that have mostly demonstrated a diminished
risk of coronary heart disease among estrogen users (Stampfer and Colditz 1991;
Barrett-Connor and Grady 1998), recent randomized clinical trials have failed to
show any reduction in cardiac events (Hulley et al. 1998; Rossouw et al. 2002;
Cherry et al. 2002) or progression of coronary atherosclerosis (Herrington et al.
2000) by postmenopausal estrogen therapy. Clearly more studies are needed to
explain the controversial results between observational studies and clinical trials,
especially on the effects of unopposed estrogen on cardiovascular risk in healthy
postmenopausal women.
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3. Aims of the study
E2 fatty acid esters are potent and long-acting metabolites of E2. The circulating
levels of E2 fatty acid esters are of particular interest, since experimental data
suggest their association with lipoproteins and their action as powerful
antioxidants. The serum concentrations of E2 fatty acid esters in human pregnancy
are not known. Moreover, no previous study has reported the effect of
postmenopausal estrogen therapy on serum E2 ester levels.
The specific aims of the present study were:
1 To develop a method for the isolation and quantitative analysis of E2 fatty acid
esters (I)
2 To determine E2 fatty acid ester concentrations in human pregnancy serum and
in ovarian follicular fluid (I)
3 To determine the concentration and distribution of human endogenous E2 fatty
acid esters in lipoproteins (II)
4 To investigate the effects of oral and transdermal estrogen and placebo
treatment on serum E2 fatty acid ester concentrations in postmenopausal
women (III)
5 To compare the effects of oral and transdermal high-dose estrogen therapy on
serum E2 fatty acid ester concentrations in postmenopausal women with
previous intrahepatic cholestasis of pregnancy and in healthy controls (IV)
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4. Materials and methods
4.1. Subjects and study designs
4.1.1. 17β-Estradiol fatty acid esters in pregnancy
serum, lipoproteins, and ovarian follicular fluid
(Studies I and II)
Early pregnancy blood samples were obtained at 7-10 weeks of gestation from
women who had received treatment for infertility by induction of ovulation (Study
I). Late pregnancy blood samples were obtained at 37-42 weeks of gestation from
healthy women (Studies I and II). Ovarian follicular fluid was obtained from ten
women undergoing ovarian stimulation for in vitro fertilization. Pooled human
serum from 50-60 male donors, purchased from the Finnish Red Cross, Helsinki,
was used as a control.
4.1.2. Effect of estrogen therapy on serum 17β-estradiol
fatty acid esters in postmenopausal women (Study III)
Postmenopausal women were randomized to receive either oral E2 (2 mg/d, n=9),
transdermal E2 (50 µg/d, n=10), or placebo (n=7) treatment for 12 weeks, as
described by Vehkavaara et al. (2000). Serum E2 fatty acid ester and E2
concentrations were determined at 0 and 12 weeks. To compare E2 fatty acid
ester/E2 ratios in menstruating and postmenopausal women, serum E2 fatty acid
ester concentrations were also measured in seven healthy young women. Blood
was obtained from one subject during the follicular phase (day 2 of the menstrual
cycle) and from six subjects during the luteal phase (days 16 to 26 of the
menstrual cycle). Pooled human male serum was used as a control (the Finnish
Red Cross).
4.1.3. Oral and transdermal estrogen therapy in women
with previous intrahepatic cholestasis of pregnancy and
in healthy controls (Study IV)
Altogether 20 postmenopausal women with a history of ICP during the years
1961-1980 and 20 healthy age-matched postmenopausal control women with ≥1
normal pregnancy during the same years were recruited; the present study
involved 10 women with previous ICP and their controls. The diagnosis of ICP
was based on generalized skin itching combined with consistent increases in
serum transaminases >35 U/l. At baseline, the patients and their controls were
matched for age. Baseline characteristics in women with and without previous
ICP were comparable (Table 1). The design was a double-blind crossover study.
The subjects were randomized to receive increasing doses of either E2 valerate
orally or E2 transdermally for 6 weeks. After a 4-week wash-out period, the
subjects crossed over to the alternate estrogen treatment for a further 6 weeks.
Medroxyprogesterone acetate (MPA) was coadministered during the last two
weeks of each 6-week cycle of estrogen treatment (Figure 3).
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Table 1. Baseline characteristics (median, interquartile range 25%, 75%) in
postmenopausal women with a history of intrahepatic cholestasis of pregnancy
(ICP; n=10) and postmenopausal control women (control; n=10). a) n=9 in both
ICP and control groups. BMI, body mass index.
Figure 3. Design of Study IV.
The serum samples before and after four weeks of either oral or transdermal
estrogen treatment were assessed for E1, E2, E2 fatty acid esters, SHBG, total
cholesterol, triglycerides, LDL and HDL cholesterol, and the hepatic enzymes
alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), and
gamma-glutamyl transferase (γ-GT).
4.2. Methods
4.2.1. Collection and storage of blood and ovarian
follicular fluid samples
Serum was prepared by centrifugation, usually within one hour, and stored at -20
ºC or -80 ºC until analyzed. Lipoprotein fractions were isolated from serum by
sequential ultracentrifugation as described below and stored at -80 ºC (Study II).
Follicular fluid samples were pooled aspirates of several ovarian follicles from the
same subject. After collection, follicular fluid was centrifuged twice to remove
blood cells and granulosa cells and stored at -80 ºC.
Oral or transdermal E2 Wash-out Oral or transdermal E2
2 mg/d or 4 mg/d or + MPA 2 mg/d or 4 mg/d or + MPA
50 µg/d 100 µg/d 10 mg/d 50 µg/d 100 µg/d 10 mg/d
X X X X
0 2 4 6 10 12 14 16
X = Serum estrogens,
lipids, hepatic enzymes Time (weeks)
Age Time from Time from BMI
(yr) menopause (yr)a pregnancy (yr)  (kg/m2)
ICP 55 (53, 58) 3.6 (3.2, 7.6) 31 (29, 31) 24.5 (24.0, 28.0)
Control 56 (55, 59) 4.2 (2.3, 7.5) 28 (27, 32) 26.5 (24.8, 28.0)
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4.2.2. Quantitative method for 17β-estradiol fatty acid
esters
Solvents
Methanol, hexane and ethyl acetate were of HPLC grade and diethyl ether of glass
distilled grade (Rathburn Chemicals Ltd, Scotland). Chloroform (Uvasol) was
purchased from Merck KGaA (Germany), and tetrahydrofuran from Sigma
Chemical Co (U.S.A.).
Chromatographic equipment
Sephadex LH-20 was purchased from Pharmacia Biotech (Sweden), Sep-Pak C18
cartridges from Waters Corp. (U.S.A) and Lipidex-5000 from Packard Bioscience
B.V. (The Netherlands). Chromatographic gels and Sep-Pak C18 cartridges were
washed prior to use, and gel suspensions were stored at 4 ºC.
Estrogens and control serum samples
Non-radioactive estrogens (E2, E2 17-stearate) were purchased from Steraloids,
Inc., U.S.A. Tritium-labeled E2 3,17-dioleate was synthesized from [2,4,6,7-
3H]-
E2 (2.7 x 10
12 Bq/mmol; NEN Life Sciences, Inc., U.S.A) and was used as an
internal standard in the E2 fatty acid ester quantitative method. The labeled
internal standard E2 3,17-dioleate was purified by Sephadex LH-20 column
chromatography before every assay and stored at 4 ºC in hexane. E2 was stored at
4 ºC in methanol.
 Low, medium, and high control serum samples for the E2 fatty acid ester
method were prepared by adding a representative E2 fatty acid ester, E2 17-
stearate, in tetrahydrofuran to pooled male serum (the Finnish Red Cross,
Helsinki) at three different concentrations, corresponding to E2 concentrations of
110 pmol/l, 257 pmol/l and 598 pmol/l. Before addition to serum, the
concentration of E2 17-stearate standard solution was confirmed both
spectrophotometrically and after hydrolysis of the esters, by GC-MS in the
selected ion monitoring mode (Adlercreutz et al. 1993). After overnight mixing at
4 ºC, the control sera were divided into 1.1 ml fractions and stored at -20 ºC.
Time-resolved fluoroimmunoassay reagents
Tris-HCl buffer (pH 7.8) was used as the assay buffer: Tris 50 mmol/l, NaCl 8.78
g, sodium azide 0.5 g, BSA (Sigma Chemical Co) 5.0 g, Tween 40 0.1 ml, aq.
steril. ad 1000 ml. Commercial E2 TR-FIA kits (DELFIA Estradiol) were
purchased from Wallac Oy, Finland.
Instrumentation
E2 TR-FIA was performed with instruments  purchased from Wallac Oy (DELFIA
Platewash, DELFIA Plateshake, and VICTOR 1420 multilabel counter with a
software version for time-resolved fluorescence measurements). Radioactivity
was measured by liquid scintillation counting (Rack-beta, Wallac Oy).
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Analysis of  serum 17β-estradiol  and 17β-estradiol fatty acid esters
Tritium-labeled E2 3,17-dioleate was added to serum, gel-filtered lipoprotein, or
ovarian follicular fluid samples as an internal standard, followed by extraction of
E2 and its lipophilic conjugates with 2.5 volumes (v) of diethyl ether:ethyl acetate
(1:1, v/v) (Figure 4). After extraction, Sephadex LH-20 column chromatography
was carried out to separate E2 fatty acid esters from nonesterified E2 (Meng et al.
1999). Small columns in Pasteur pipettes were used (5 mm × 50 mm, internal
diameter × height, Sephadex LH-20 in chloroform:hexane, 1:1, v/v): the nonpolar
E2 fatty acid ester fraction was first eluted with chloroform:hexane (1:1, v/v). The
more polar nonesterified E2 fraction was then eluted from the column with
methanol. To hydrolyze E2 fatty acid esters, the E2 ester fraction was saponified at
60 ºC for 2 h in methanolic KOH. After saponification, the samples were
neutralized with distilled water and HCl and subjected to further chromatographic
purification. To remove excess salt, the hydrolyzed E2 ester fraction was washed
with water on Sep-Pak C18 cartridges and eluted with methanol. Lipidex-5000
reversed-phase column chromatography (5 mm × 50 mm, internal diameter ×
height, Lipidex-5000 in methanol:water:chloroform, 8:2:2, v/v and the same
solvent as the eluent) was used to remove cholesterol (Hämäläinen 1982). Finally,
a second Sephadex LH-20 column chromatography (chloroform:hexane, 1:1, v/v)
was carried out to remove additional interfering lipids such as free fatty acids: the
lipophilic impurities were first removed with chloroform:hexane (1:1, v/v),
followed by elution of the hydrolyzed E2 ester fraction with methanol.
To analyze E2 and hydrolyzed E2 ester concentrations, commercial E2 TR-FIA
kits were used with the following modifications to the assay procedure. The
calibrators for TR-FIA, ranging from 11.5 pmol/l to 1836 pmol/l, were made from
an E2 standard solution in methanol by serial dilutions with the assay buffer. The
concentration of E2 in the standard solution was confirmed both by
spectrophotometer and by GC-MS (Adlercreutz et al. 1993). Compared to the kit
protocol, the E2 antiserum and europium tracer solution were 50% more diluted.
The precision profile of the modified TR-FIA was calculated from 9 duplicate
measurements of each calibrator. The working range was 55 pmol/l to 1840
pmol/l if a coefficient of variation (CV) of 10% was taken as the discrimination
limit, and 38 pmol/l to over 1840 pmol/l if a CV of 15% was accepted.
The serum samples were concentrated twofold prior to measurement, except
for late pregnancy serum samples (Studies I and II). The results were calculated
by correcting for recovery according to the radioactive internal E2 ester standard,
and for volume. In addition, in the methodological Study I, the value of pooled
human male serum was considered as blank and was therefore subtracted from the
pregnancy serum values. In the later studies, however, subtraction of the value of
male serum was not performed. E2 fatty acid ester concentrations are expressed as
picomoles or nanomoles of E2 equivalents per liter.
Quality control
Analyses of serum E2 and its fatty acid ester derivatives were carried out in
duplicate whenever possible (Studies I and IV). In Studies II, III, and IV, the
samples of each subject were usually analyzed in a single assay to minimize the
effect of inter-assay variation. In randomized Studies III and IV, in which
different estrogen therapies and placebo treatment were compared, the samples
were analyzed blind to avoid bias. Low, medium, and high control serum samples
were included in all the E2 fatty acid ester assays. If one control serum sample
exceeded the ±3 SD control limit, or was repeatedly over the ±2 SD limit, the
analysis was repeated.
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Figure 4. Flow chart of the quantitative method for E2 fatty acid esters.
4.2.3. Sequential ultracentrifugation and purification of
serum lipoproteins
Lipoproteins (VLDL, LDL, HDL2, and HDL3) were isolated from serum by
sequential ultracentrifugation (Havel et al. 1955). In addition to individual
lipoprotein fractions, a total lipoprotein fraction (containing the VLDL, LDL, and
HDL fractions) was isolated from serum by a single ultracentrifugation at a
density of 1.21 g/ml. Ultracentrifugally isolated lipoprotein fractions were
purified of unbound estrogens and other low molecular weight contaminants by
1 ml or 2 ml of serum or 0.5 ml of follicular fluid
add 3H-labeled internal standard
extract with 4 x 2.5 vols. diethyl ether/
ethyl acetate (1:1)
Sephadex LH-20 column chromatography (I)
  
       E2 fatty acid ester fraction Nonesterified E2 fraction
 elute with chloroform/hexane (1:1) elute with methanol
         saponify and neutralize dilute in assay buffer
analyze by TR-FIA
       Sep-Pak C18 cartridge
elute unesterified E2 with
 methanol
       Lipidex-5000 reversed-phase
 column chromatography
elute E2 with methanol/H2O/
chloroform (8:2:2)
    Sephadex LH-20 chromatography (II)
 elute E2 with methanol
dilute in assay buffer
determine recovery by liquid
scintillation counting
                 
analyze by TR-FIA 
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size-exclusion gel filtration, using a Sephadex G-25 column (column dimensions
1 × 20 cm; Pharmacia Biotech, Sweden). Lipoproteins eluted with phosphate-
buffered saline (pH 7.4) in the void volume. The protein concentration in each
lipoprotein fraction was determined before and after gel filtration (Lowry et al.
1951). Total lipoprotein fractions isolated by a single ultracentrifugation at a
density of 1.21 g/ml were assessed for contamination by serum albumin, but were
found to contain no detectable albumin as determined by sodium dodecyl sulfate
polyacrylamide gel electrophoresis with Coomassie blue staining.
The concentration of E2 fatty acid esters in the lipoprotein fractions was
calculated by correcting for recovery of the tritiated internal E2 ester standard
added to the isolated and purified lipoprotein fractions. Estrogen concentrations in
the total lipoprotein fraction isolated by a single ultracentrifugation were also
corrected according to the recovery of cholesterol in lipoprotein
ultracentrifugation, as well as the recovery of protein in gel filtration on Sephadex
G-25.
4.2.4. Other analytical methods
The concentrations of unlabeled estrogen standard solutions (E2 and E2 17-
stearate) were measured at λ=280 nm with a Shimadzu UV 1202
spectrophotometer in quartz cuvettes (diameter, 1 cm). GC-MS in the selected ion
monitoring mode (Adlercreutz et al. 1993) was also used as a reference method
for determining the estrogen concentrations in standard solutions. The purity of
3H-E2 3,17-dioleate was investigated by thin layer chromatography (TLC) on a
silica plate in ethyl acetate:hexane (3:7, v/v) with E2 3,17-distearate,
 E2 3-oleate,
E2 17-stearate, and E2 as reference compounds.
The serum E1 concentration was determined by RIA (Estron, Diagnostic
Systems Laboratories, Germany). The serum SHBG concentration was measured
by TR-FIA (AutoDELFIA SHBG, Wallac Oy, Finland). The serum concentrations
of free, nonprotein-bound E2 were calculated as described by Moore et al. (Moore
et al. 1982; Hämäläinen et al. 1986). Cholesterol and triglyceride concentrations
in serum and ultracentrifugally isolated lipoprotein fractions were measured by
enzymatic methods (ABX Diagnostics, France). In Study IV, HDL2 and HDL3
cholesterol concentrations were measured (Roche Diagnostics GmbH, Germany)
after precipitation of VLDL and LDL by heparin-manganese chloride (Gidez et al.
1982). The LDL cholesterol concentration was calculated using the formula of
Friedewald (1972), the upper limit of serum triglyceride concentration was 4
mmol/l. Plasma ALAT, ASAT, and γ-GT activities were determined by kinetic
methods.
4.2.5. Statistical analyses
Statistical analyses were performed using SPSS 10.07 software (U.S.A.). Data are
expressed as the median (range or interquartile range 25%, 75%) or mean
(standard deviation, SD, or standard error of the mean, SEM). The Wilcoxon
signed ranks test, or the paired t-test for parameters that were normally
distributed, was performed for pairwise comparisons within the group. Between-
group differences were assessed by the Mann-Whitney test, and the unpaired t-
test, when appropriate. Correlation analyses were performed using Spearman’s
non-parametric correlation coefficient, or Pearson’s correlation coefficient in case
the data were symmetrically distributed. The level of significance was P<0.05.
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5. Results
5.1. Quantitative 17β-estradiol fatty acid ester
method (Study I)
Sensitivity
The lower limit of detection (Anderson 1989) of the E2 fatty acid ester method,
defined as the concentration at the mean + 3 SD of 15 duplicate determinations of
1 ml of pooled human male serum, was 44 pmol/l. Male serum was used to
determine the detection limit in order to take into consideration the possible
interfering effect of serum matrix components, such as lipids, proteins, and salt
(Stenman 1997).
Imprecision
The imprecision of the E2 fatty acid ester method was calculated from
determinations of the low, medium, and high control serum samples of human
male serum with added E2 17-stearate. Eight to nine duplicate determinations of
the low, medium, and high control samples gave intra-assay CVs of 10%, 6.2%,
and 4.2%, respectively. No corrections for procedural losses according to
recovery of the labeled internal standard were performed in the calculation of the
intra-assay CVs.
Interassay imprecision was calculated from 14 consecutive assays (all the
assays of Studies II and III), using the same batch of control serum samples. The
CVs for low, medium, and high control samples are shown below in Table 2.
Table 2. Recovery of E2 17-stearate added to male serum samples. The results are
expressed as means and calculated from duplicate determinations in 13 to 14
consecutive assays (n, number of assays). E2 17-stearate concentrations are
expressed as pmol/l E2.
Recovery
Analytical recoveries of known amounts of unlabeled E2 17-stearate added to
male serum samples are shown in Table 2. The results are expressed as means of
13 to 14 assays and were calculated by correcting for procedural losses according
to recovery of the radiolabeled internal E2 ester standard, and by subtracting the
value of male serum with no E2 17-stearate added.
E2 17-stearate added E2 ester recovered CV
pmol/l pmol/l % % n
110 (low control) 121 110 13.2 13
257 (medium control) 262 102 14.0 14
598 (high control) 577 96 18.8 13
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The mean (SD) recovery of the radiolabeled internal E2 ester standard added to
the serum samples was 72% (6.4) in seven consecutive assays (Study III, number
of determinations n=121).
In the analysis of serum nonesterified E2 (Figure 4), the mean recovery of the
tritium-labeled E2 standard after extraction and chromatography on Sephadex LH-
20 was 96% (n=3).
Parallel ism of the assay
E2 fatty acid esters were extracted from ovarian follicular fluid and serum
samples; isolated, saponified, and purified by chromatography (see Figure 4),
followed by serial dilution with the assay buffer and analysis by E2 TR-FIA.
Dilution curves paralleled the standard curve of E2 TR-FIA (Table 3).
Table 3. Dilution parallelism of ovarian follicular fluid and serum samples
containing hydrolyzed E2 fatty acid esters. The results are expressed as pmol/l E2.
Specificity
The reported cross-reactivity of the commercial E2 antiserum for plasma steroids
was low: 0.75% for E1 and 0.40% for E3. However, because pregnancy serum
contained high concentrations of E3, E1, and DHEA and their conjugates, several
experiments were made to exclude the possibility that interfering amounts of these
steroids were present after the chromatographic purification steps. Most of the
E2 fatty acid ester, pmol/l
Sample Dilution factor Observed Expected % of expected
Follicular fluid 1 2 844 914 93
5 940 914 103
10 925 914 101
20 907 914 99
Follicular fluid 2 2 2305 2254 102
5 2452 2254 109
10 2258 2254 100
20 2276 2254 101
Late pregnancy serum 2 977 859 114
4 1028 859 120
8 932 859 109
Male serum with added
E2 17-stearate  2.5 1377 1465 94
5 1402 1465 96
10 1413 1465 96
20 1465 1465 100
40 1468 1465 100
80 1483 1465 101
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hydrophilic steroid conjugates remained in the water phase in the initial extraction
with organic solvents. To show that E3 and E1 did not interfere with the analysis of
pregnancy serum samples, an additional Sephadex LH-20 column
chromatography (9% methanol in toluene) (Adlercreutz et al. 1981) was
performed after saponification and purification of the samples on Sep-Pak C18.
This removed E3 and E1 from the samples, which still gave similar results in E2
TR-FIA compared with the usual method. Finally, experiments with tritium-
labeled DHEA and pregnenolone showed that they did not co-elute with the E2
ester fraction in the final Sephadex LH-20 chromatography (Figure 4).
The completeness of the separation of E2 fatty acid esters from nonesterified E2
by Sephadex LH-20 column chromatography (Figure 4, chromatography I) was
confirmed by several experiments. A wide range of E2 concentrations was added
to male serum as well as to control serum samples (480 pmol/l corresponding to
high serum E2 values during postmenopausal estrogen therapy; 43 nmol/l, 106
nmol/l, and 150 nmol/l corresponding to serum E2 values in pregnancy) and
analyzed for E2 fatty acid esters by TR-FIA. In all of these experiments, the male
and control serum samples with added E2 gave E2 ester values that were within the
normal range. Also, varying amounts (5.6 ng to 5.9 µg) of unlabeled E2 standard
were applied to the Sephadex LH-20 column. The first fraction (E2 ester fraction)
eluted from the column was analyzed by E2 TR-FIA as well as by GC-MS and
showed that negligible amounts of nonesterified E2 was eluted with chloroform-
hexane in the E2 ester fraction.
5.2. 17β-Estradiol fatty acid esters in pregnancy
serum and lipoproteins (Studies I and II)
5.2.1. Serum 17β-estradiol fatty acid esters in
pregnancy
The serum E2 fatty acid ester concentration (median, interquartile range 25%,
75%) was 39 (28, 50) pmol/l in early pregnancy, and 365 (280, 540) pmol/l in late
pregnancy (Study I). These values were calculated by correcting for volume and
recovery, and by subtracting the value of male serum. If calculated without
subtracting the male serum value, as in Study II, the median E2 ester concentration
in Study I in early pregnancy was 70 (61, 83) pmol/l and in late pregnancy 470
(393, 585) pmol/l, and the mean proportion of E2 esters to nonesterified E2 ranged
between 1.3% and 0.5% in early and late pregnancy, respectively. In Study II, the
median serum E2 fatty acid ester concentration was 481 (309, 703) pmol/l and the
mean proportion of serum E2 esters to nonesterified E2 was 0.7% in late
pregnancy, in agreement with Study I. Figure 5A demonstrates the positive
correlation between serum E2 and its fatty acid ester derivative concentrations in
early and late pregnancy. However, the proportion of serum E2 esters to E2
diminished as the serum nonesterified E2 concentration grew higher in pregnancy
(Figure 5B). In Figure 5, the results for Studies I and II were calculated similarly:
by correcting for volume and recovery only and not subtracting the value of male
serum from the pregnancy serum values.
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Figure 5A. Relationship between serum nonesterified E2 and serum E2 fatty acid
ester concentrations during pregnancy in Study I (early and late pregnancy) and
in Study II (late pregnancy)(Spearman’s correlation). B. Relationship between
serum E2 concentration and the proportion of serum E2 fatty acid esters to serum
E2 in early and late pregnancy (Spearman’s correlation). The percentage was
calculated as [E2 ester (pmol/l) / E2 (pmol/l)] × 100.
5.2.2. Estrogens in pregnancy lipoproteins
17β-Estradiol  fatty acid esters
Most of the serum E2 fatty acid esters, a mean of 75%, were recovered in the total
lipoprotein fraction (Table 4). As shown in Figure 7, a strong positive correlation
existed between the E2 fatty acid ester concentrations measured in the total
lipoprotein fraction and in whole serum (r=0.976, P<0.001). The serum E2 fatty
acid ester concentration also correlated significantly with the E2 ester
concentrations in the LDL (r=0.879; P=0.001) and HDL3 fractions (r=0.770,
P=0.009) (Figure 7).
Most of the lipoprotein E2 fatty acid esters were recovered in the HDL (HDL2
+ HDL3) and LDL fractions, 54% and 28%, respectively (Table 4). In LDL, the
median E2 ester concentration, expressed relative to the LDL protein
concentration (mg/l), was 0.16 (0.05 to 0.38) pmol/mg. The E2 fatty acid ester
concentration in the LDL correlated positively with the serum nonesterified E2
levels (Figure 6). The E2 ester concentration in the HDL3 fraction correlated
positively with the E2 ester concentrations in other lipoprotein fractions: VLDL
(r=0.758, P=0.011), HDL2 (r=0.648, P=0.043), and most significantly with that in
the LDL fraction (r=0.879, P=0.001). The E2 ester to cholesterol ratio was greatest
in the HDL fraction.
Nonesterified 17β-estradiol
In addition to E2 esters, concentrations of nonesterified E2 were determined in
lipoproteins. The median E2 level detected in the total lipoprotein fraction isolated
by single ultracentrifugation was 0.2% of the late pregnancy serum E2 levels
(Table 4). There was a statistically significant positive correlation between the
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serum nonesterified E2 and the nonesterified E2 concentrations measured in the
total lipoprotein fraction (r=0.806, P=0.005). In most of the subjects, however,
nonesterified E2 was not detected in isolated individual lipoprotein fractions
(VLDL, LDL, and HDL subfractions 2 and 3). Nonesterified E2 was detectable in
VLDL in three, in LDL in four, and in the HDL2 subfraction in four subjects
(Table 4).
Table 4. E2 fatty acid ester and E2 concentrations in the serum and lipoprotein
fractions of ten women in late pregnancy. The data are expressed as medians
(interquartile range 25%, 75%) except for E2 concentrations in the VLDL, LDL,
and HDL2 fractions. 
a)The data are expressed as ranges (n, number of subjects).
Figure 6. The relationship between serum nonesterified E2 and LDL E2 fatty acid
ester concentrations in late pregnancy (Spearman’s correlation).
0
50
100
150
200
250
300
0 100 200 300 400
LDL E2 fatty acid ester (pmol/l)
S
er
u
m
 E
2 
(n
m
ol
/l)
r=0.770, P =0.009, n=10
E2 ester (pmol/l) E2 (pmol/l)
detectable undetectable
Serum 481 (309, 703) 69 500 (42 800, 104 000) -
Total lipoprotein 362 (249, 519) 136 (92, 264) -
VLDL 58 (50, 129) 35-105 (n=3) a <35 (n=7)
LDL 130 (68, 188) 39-264 (n=4) a <35 (n=6)
HDL2 121 (104, 212) 58-283 (n=4)
 a <35 (n=6)
HDL3 102 (46, 145) - <35 (n=10)
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Figure 7. Relationship between E2 fatty acid ester concentrations measured in
serum and in the total lipoprotein, LDL, and HDL3 fractions in late pregnancy
(Spearman’s correlation).
5.3. 17β-Estradiol fatty acid esters in ovarian
follicular fluid (Study I)
Ovarian follicular fluid had a high concentration of E2 fatty acid esters, a mean
(SD) of 106 (61) nmol/l. The mean concentration of nonesterified E2 in the
follicular fluid was 1900 (1230) nmol/l and the proportion of E2 fatty acid esters to
nonesterified E2 was 6% (range, 3% to 10%). There was a statistically significant
positive correlation between the follicular fluid E2 fatty acid ester and
nonesterified E2 concentrations (r=0.811, P=0.001).
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5.4. Effect of estrogen therapy on concentrations of
serum 17β-estradiol fatty acid esters in
postmenopausal women (Study III)
17β-Estradiol fatty acid ester and nonesterified 17β-estradiol
concentrations
In the oral E2 group (2 mg/d), the median concentration of serum E2 fatty acid
esters increased statistically significantly by 27% during 12 weeks of treatment
(P=0.028), but remained unchanged in the transdermal E2 (50 µg/d) and placebo
groups (Table 5 and Figure 8). Serum nonesterified E2 concentrations rose more in
the group receiving oral E2 compared with transdermal E2 treatment (Table 5).
The positive correlation between the change in serum E2 ester concentration and
the change in serum nonesterified E2 concentration during 12 weeks of treatment
in the oral and transdermal E2 and placebo groups is shown in Figure 9. The
calculated concentrations of free (nonprotein-bound) E2 were comparable in the
oral and transdermal groups at 12 weeks (Table 5) because the serum SHBG
concentrations increased significantly in the oral (P=0.008, 12 vs. 0 wk) but not in
the transdermal E2 group.
 Table 5. Effect of 12 weeks of oral (n=9) and transdermal E2 (n=10) and placebo
(n=7) treatment on serum E2 fatty acid ester and E2 concentrations (median,
interquartile range 25%, 75%) in postmenopausal women. *)P=0.028, **)P<0.01
12 vs. 0 wk, Wilcoxon signed ranks test.
Serum 17β-estradiol fatty acid ester concentrations and forearm
blood flow responses
The change in serum E2 fatty acid ester concentration in all subjects during the
study (oral and transdermal E2 and placebo group, n=26) was positively correlated
with the changes in endothelium-dependent (intra-arterial infusion of
acetylcholine 7.5 and 15 µg/min) and endothelium-independent vasodilatation (10
µg/min of sodium nitroprusside), as previously measured by Vehkavaara and
coworkers (2000) (Figure 10). No correlation, however, was observed between
the change in serum nonesterified E2 concentrations and the changes in forearm
E2 fatty acid Nonesterified Free, nonprotein-
ester (pmol/l) E2 (pmol/l) bound E2 (pmol/l)
Oral E2 group
0 wk 77 (68, 90) 34 (25, 403) 0.6 (0.4, 4.4)
12 wk 98 (85, 122)* 318 (253, 457) 2.4 (1.9, 3.8)
Transdermal E2 group
0 wk 82 (75, 87) 34 (28, 44) 0.6 (0.5, 0.7)
12 wk 83 (74, 90) 165 (114, 273)** 2.7 (1.9, 4.3)**
Placebo group
0 wk 85 (79, 105) 36 (30, 45) 0.7 (0.4, 0.8)
12 wk 82 (73, 91) 35 (28, 52) 0.6 (0.5, 0.9)
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blood flow responses during treatment, in agreement with the previous study
(Vehkavaara et al. 2000).
Figure 8. Individual serum E2 fatty acid ester concentrations at 0 weeks and after
12 weeks of oral and transdermal E2 and placebo treatment. The median serum E2
fatty acid ester concentration rose in the oral E2 group (P=0.028) but remained
unchanged in the transdermal E2 and placebo groups (Wilcoxon signed ranks
test).
 Figure 9. The relationship between the change in serum E2 fatty acid ester
concentration and the change in serum nonesterified E2 concentration at 12 weeks
vs. 0 weeks of oral and transdermal E2 and placebo treatment in postmenopausal
women (Spearman's correlation).
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Figure 10. The relationship between the change in serum E2 fatty acid ester
concentration and the change in forearm blood flow in postmenopausal women
(n=26) at 12 weeks of oral or transdermal E2 or placebo treatment vs. 0 weeks.
The change in serum E2 ester concentration correlated positively with the change
in acetylcholine 7 µg/min, acetylcholine 15 µg/min, and sodium nitroprusside 10
µg/min -induced blood flow responses (Spearman's correlation). ACh,
acetylcholine; SNP, sodium nitroprusside.
17β-Estradiol fatty acid ester and nonesterified 17β-estradiol
concentrations in young women and in men
The median (range) serum E2 fatty acid ester concentration in young menstruating
women (n=7) was 75 (62 to 110) pmol/l, in the same range as the serum E2 ester
level in postmenopausal women (n=26) at baseline, 80 (38 to 120) pmol/l (P=NS).
In pooled male sera, the measured serum E2 fatty acid ester concentration (52
pmol/l) was lower than in the postmenopausal women (P=0.001), despite the
higher median concentration of nonesterified E2 in male serum (72 pmol/l)
compared with postmenopausal women (34 pmol/l). The median serum E2 fatty
acid ester to serum nonesterified E2 ratio was 2.2 (0.2 to 4.9) in postmenopausal
women, 0.3 (0.1 to 0.6) in young women, and 0.7 (0.6 to 1.0) in pooled human
male serum.
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5.5. Oral and transdermal estrogen therapy in women
with previous intrahepatic cholestasis of pregnancy
and in healthy controls (Study IV)
Serum estrogens and SHBG
Four weeks’ administration of E2 valerate orally, 2-4 mg/d, increased the median
serum E2 concentration in the ICP and control women to a greater extent than four
weeks of transdermal E2  administration 50-100 µg/d in the same subjects (Table
6). The serum E2 fatty acid ester concentration rose during oral estrogen therapy
in the ICP and control women, but this increase reached statistical significance in
the control group only (Table 6). In contrast, transdermal estrogen therapy did not
cause any statistically significant changes in the serum E2 fatty acid ester
concentrations in either group (Table 6). In line with the higher estrogen dose
during oral administration, the median serum E1 and SHBG concentrations in the
ICP and in the control group rose more during oral than during transdermal E2
therapy (Table 6). The median serum estrogen and SHBG levels were lower in the
ICP group compared with the control group throughout the study, but only the
difference in the serum E1 level during transdermal E2 therapy reached statistical
significance (P=0.023, ICP vs. control group at 4 wk of transdermal E2 treatment).
Therefore, serum E2 ester concentrations during oral and transdermal E2
administration are also shown for the combined ICP and control group (Figure
11).
Table 6. The median (interquartile range 25%, 75%) concentrations of serum E2
fatty acid esters, nonesterified E2, E1, and SHBG before and after four weeks of
oral and transdermal estrogen therapy in postmenopausal women with a history
of intrahepatic cholestasis of pregnancy (ICP, n=10) and in control women
(control, n=10). *)P<0.05, **)P<0.01, 4 wk of estrogen therapy vs. pretreatment
(Wilcoxon signed ranks test).
E2 ester (pmol/l) E2 (pmol/l) E1 (pmol/l) SHBG (nmol/l)
Pretreatment (oral)
ICP 57 (49, 84) 30 (23, 34) 74 (62, 183) 49 (41, 93)
Control 56 (43, 74) 48 (23, 61) 169 (137, 235) 61 (40, 89)
Oral estrogen
ICP 73 (60, 97) 302 (143, 370)** 2 090 (1 510, 3 250)** 121 (88, 166)**
Control 74 (60, 100)** 366 (270, 477)** 3 720 (2 180, 7 210) ** 145 (108, 195)**
Pretreatment (transdermal)
ICP 54 (41, 87) 28 (24, 35) 80 (51, 189) 55 (45, 85)
Control 59 (46, 69) 41 (26, 60) 139 (117, 208) 63 (40, 91)
Transdermal estrogen
ICP 61 (44, 89) 208 (111, 375)** 128 (76, 234)* 69 (51, 89)
Control 49 (42, 58) 222 (204, 271)** 254 (181, 362)** 77 (44, 97)
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Figure 11. The median (interquartile range 25%, 75%) serum E2 fatty acid ester
concentrations at 4 wk vs. 0 wk of oral and transdermal estrogen therapy in the
combined ICP and control group (n=20) (Wilcoxon signed ranks test). NS, not
significant.
Serum lipids and hepatic enzymes
There were no statistically significant differences in serum lipid levels at baseline
or during the study between the ICP and the control group. Serum total cholesterol
decreased statistically nonsignificantly in both groups during oral and transdermal
E2 therapy. Oral E2 therapy decreased the serum LDL cholesterol and increased
the hormone-sensitive HDL2 cholesterol levels in both groups (Figure 12). In both
ICP and the control group, HDL3 cholesterol levels remained unchanged or
slightly decreased during oral and transdermal E2 therapy. Oral E2 administration
increased plasma ASAT, ALAT, and γ-GT activities in the ICP women, but none
of these changes reached statistical significance. However, the mean (SEM)
activities of plasma ASAT, ALAT, and γ-GT were statistically significantly
higher in the ICP group as compared with the control group after four weeks of
oral E2 administration: 37 (5.7) vs. 23 (1.2) U/l, 15 (2.0) vs. 9.9 (1.5) U/l, and 40
(12) vs. 23 (7.2) U/l, respectively (P<0.05, ICP vs. control group; t test and Mann-
Whitney test). Except for the slightly elevated mean plasma ASAT at four weeks
of oral E2 therapy, the mean activities of ASAT, ALAT, and γ-GT in the ICP
group remained in the normal range.
Correlation between serum estrogens, SHBG, and lipids
In the combined ICP and control group (n=20), after four weeks of oral estrogen
therapy, the serum E2 fatty acid ester concentration correlated positively with the
serum nonesterified E2 (r=0.477, P=0.034), E1 (r=0.656, P=0.002), and SHBG
concentrations (r=0.498, P=0.026). Also, the change in serum E2 fatty acid ester
concentration during oral E2 treatment correlated positively with the changes in
serum E2, E1, and SHBG concentrations (Figure 13). None of the serum lipids,
such as total HDL or its subfraction cholesterol levels, correlated with the serum
E2 fatty acid ester levels during administration of E2 by either route.
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Figure 12. The mean (SD) serum LDL and HDL2 cholesterol concentrations at
baseline and at 4 wk of oral and transdermal estrogen therapy in postmenopausal
women with previous intrahepatic cholestasis of pregnancy (ICP, n=10) and
control women (control, n=10). *)P<0.05, **)P<0.01, 4 wk vs. 0 wk (paired t test).
Figure 13. The relationship between the change in serum E2 fatty acid ester
concentration and the change in serum nonesterified E2 (Spearman’s correlation),
E1 (Spearman’s correlation), and SHBG concentrations (Pearson’s correlation)
during four weeks of oral E2 administration in women with previous cholestasis of
pregnancy (ICP, n=10) and in control women (control, n=10).
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6. Discussion
6.1. Evaluation of the study methods and design
The quantitative method for 17β-estradiol fatty acid esters
A commercial E2 TR-FIA was chosen as the analytical method because it was
more rapid and easier to carry out than the traditional RIAs. The automated
washing of unbound label from bound label contributed to the low non-specific
binding in the assay. The small sample volume (25 µl) in the reaction mixture
(225 µl) was also an advantage, potentially reducing the interfering effect of the
serum matrix components.
The commercial TR-FIA method was modified by adding two lower calibrators
as well as a greater dilution of both antiserum and europium tracer. This enabled
us to reliably measure the E2 concentrations of 38 pmol/l or even less compared to
the lowest calibrator of the commercial TR-FIA kit of 50 pmol/l. Because the kit
was designed for direct serum E2 measurements and our E2 fatty acid ester method
contained many chromatographic purification steps, the calibrators for E2 TR-FIA
were made by serial dilutions with assay buffer instead of using commercial
serum-based calibrators.
Despite the high specificity of E2 TR-FIA and its antiserum, the isolation and
purification of E2 esters contributed to a great extent to the overall specificity of
the E2 fatty acid ester method. E2 fatty acid esters were measured as free E2 after
saponification of the esters, and therefore complete separation of the E2 esters
from the nonesterified E2 in the samples was obligatory. This was performed by
hydrophobic chromatography on a Sephadex-LH 20 column, allowing the
measurement of E2 fatty acid ester levels in pregnancy serum that contained very
high E2 levels. Another essential step was the removal of contaminating lipid
substances, including cholesterol and other fats, from samples by column
chromatography at the end of the method. The many chromatographic and other
purification steps were all carefully tested for interference with TR-FIA analysis.
The solvents and reagents used in each step, such as extraction with diethyl ether-
ethyl acetate and saponification, usually caused only small blanks in TR-FIA.
The E2 ester method showed good within- and between-run reproducibility in
the concentration range of the control serum samples, despite the many
chromatographic steps needed. The reproducibility of the method was also
evaluated at E2 ester concentrations below the level of the low control sample
(<110 pmol/l) by analyses of male serum with no added E2 ester. The intra-assay
imprecision of two-fold concentrated male serum samples was repeatedly <15%.
The between-run reproducibility of these male serum values was more variable: it
was adequate within individual studies (Studies II and III) but increased to a CV
of >20% when more analyses from a longer time period were evaluated. In the
methodological Study I, the E2 ester value of the pooled male serum was
subtracted from the pregnancy serum values. However, in the later studies in
which two-fold concentrated male serum samples were analyzed, it was
concluded that the value of male serum cannot be considered as a blank. This was
judged from the good reproducibility of these determinations and also because
they were within the working range of E2 TR-FIA. Thus, in future work, instead of
subtracting the value of male serum as in Study I, the water blank of each assay
should be subtracted from the serum E2 fatty acid ester values.
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 The accuracy of the method was good, as judged from the analytical recovery
of known amounts of a representative E2 fatty acid ester, E2 17-stearate, added to
male serum (Table 2). The recovery of the tritium-labeled internal E2 ester
standard was also adequate through all the purification steps of the method.
Unfortunately, the method lacked the analysis of “zero” serum samples, that is
human serum samples without esterified E2. Such serum was impossible to find
because many tissues synthesize E2 fatty acid esters. Even charcoal-stripping does
not remove steroid fatty acid esters from biological fluids (Roy and Bélanger
1992). Another problem was that no reference method was sufficiently sensitive
to analyze concentrations of saponified E2 fatty acid esters from human serum
samples.
In conclusion, the sensitivity of the E2 ester method was adequate for analyzing
pregnancy serum and lipoprotein as well as ovarian follicular fluid samples, and,
when concentrated twofold, postmenopausal serum samples could also be
analyzed. One disadvantage of the method was that it was laborious and time-
consuming and thus not suitable for very large studies. An ideal method would
determine E2 fatty acid ester concentrations directly, without saponification of the
esters. However, no method sensitive enough for serum analyses of intact E2 fatty
acid esters has been reported. As endogenous E2 fatty acid esters are a
heterogeneous family of long-chain fatty acid esters (Larner et al. 1993), it would
be difficult to develop a specific immunoassay, as suggested by Larner et al
(1992b).
Subjects and study designs
In Study III, the postmenopausal status of the subjects was confirmed by
laboratory (follicle stimulating hormone >30 U/l) and clinical examination
(thickness of the endometrium <6 mm) (Vehkavaara et al. 2000). Despite
fulfilling the inclusion criteria, three subjects in the oral E2 and one subject in the
placebo group had elevated (>90 pmol/l) baseline serum E2 levels. These elevated
serum E2 values were thought to be due to some residual function of the ovaries
(Padwick et al. 1985). In Study IV, the baseline serum estrogen and lipid values in
the ICP and control group were comparable, and, during the four weeks’ wash-out
period, all the serum estrogen, SHBG, and lipid values returned to pretreatment
levels.
 The effects of oral (2-4 mg/d) and transdermal (50-100 µg/d) administration of
E2 were compared in Studies III and IV. Considering that about 5% to 10% of
orally administered E2 reaches the systemic circulation as E2 (Longcope et al.
1985; Kuhnz et al. 1993), the oral E2 doses used in these studies were higher than
the transdermal doses. Consistently, the serum E2 levels obtained during oral E2
treatment were higher than with transdermal E2 treatment in both Studies III and
IV. A 2 mg/d oral dose of E2 has been shown, however, to be as effective as 50
µg/d of transdermal E2 in reducing serum gonadotrophin values in postmenopausal
women, a measure of the estrogenic effect of estrogen replacement therapy
(Powers et al. 1985).
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6.2. Endogenous 17β-estradiol fatty acid esters in
pregnancy serum and lipoproteins
The present studies showed that E2 fatty acid esters represent a quantitatively
minor estrogen metabolite in human pregnancy. Serum E2 ester concentrations in
early pregnancy were similar to those observed in nonpregnant women even
though serum nonesterified E2 concentrations were markedly elevated. Our E2
ester values in early pregnancy were in agreement with previous determinations of
E2 esters by another method in one pregnant subject at 14 weeks of gestation
(serum E2 ester level of 37 pmol/l), and in three women receiving gonadotrophin
treatment for infertility in whom serum E2 ester levels ranged between 48 to 92
pmol/l and nonesterified E2 levels were approximately 4 to 6 nmol/l,
corresponding to early pregnancy values (Larner et al. 1992b). In the present
study, serum E2 ester levels were many times higher in late as compared with
early pregnancy, but the proportion of esterified E2 to nonesterified E2 in serum
became lower with advancing gestation. The physiological role of E2 esters in
pregnancy is not known. However, their low serum levels relative to the parent
steroid E2 suggest that fatty acid esterification is not an inactivation mechanism of
estrogens.
The concentrations and distribution of endogenous E2 fatty acid esters in
human lipoproteins were determined in the present study for the first time. The
method developed in Study I for determination of E2 esters in serum was also
suitable for analysis of E2 esters in lipoprotein fractions from pregnant women.
Most of the serum E2 fatty acid esters in late pregnancy were recovered in
lipoproteins, an observation consistent with previous experimental data (Larner et
al. 1987), and there was a good correlation between E2 ester determinations in
serum and in lipoproteins. HDL was the main transporter of E2 esters in human
blood. This is in agreement with a previous study on the association of E2 esters
with rat lipoproteins in vivo (Larner et al. 1987), and with previous experimental
studies suggesting that E2 fatty acid esters are formed by LCAT in association
with HDL particles (Leszczynski and Schafer 1991; Höckerstedt et al. 2002). The
present results also suggested that the concentration of endogenous E2 fatty acid
esters in lipoproteins depended on the circulating levels of the parent steroid, E2.
This is logical, because previous studies indicate that the substrate for circulating
E2 esters is serum E2 (Jones and James 1985). Experimental studies have
demonstrated that the E2 esters formed in HDL3 particles may be further
transported to LDL (Abplanalp et al. 2000; Helisten et al. 2001). Our results
showed that, in addition to HDL, endogenous E2 esters are also incorporated in
VLDL and LDL fractions.
 Unconjugated E2 is transported in blood bound mainly by SHBG and albumin
(Dunn et al. 1981). The association of nonesterified E2 with lipoproteins other
than HDL subfraction 3 is nonspecific and weak (Leszczynski and Schafer 1991),
and it has been estimated that less than 9% of plasma E2 in normal women is
associated with lipoproteins in the circulation (Leszczynski and Schafer 1990). In
this study, lipoproteins were isolated either by a single ultracentrifugation (total
lipoprotein fraction) or by sequential ultracentrifugation, followed by purification
by gel filtration. Therefore, any weakly associated low molecular weight
substance was likely to be removed from lipoprotein fractions during the
procedure and only steroids incorporated in lipoprotein or bound to its surface
structure would remain attached. Apart from E2 esters, we detected low
concentrations of nonesterified E2, on the average 0.2% of serum E2, in the total
lipoprotein (VLDL+LDL+HDL) fraction in late pregnancy. In 29 out of the 40
individual HDL, LDL, and VLDL fractions analyzed, however, nonesterified E2
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was not detectable, and only E2 in the form of fatty acid esters was detected in
these fractions.
As the association of E2 and its fatty acid esters with lipoproteins was
investigated in late pregnancy, it is not known whether these results can be
extrapolated to nonpregnant subjects. Physiologic hyperlipidemia as well as
changes in lipoprotein composition that occur during pregnancy (Skryten et al.
1980; Winkler et al. 2000) might affect the association of steroids with
lipoproteins (Leszczynski and Schafer 1989). With the currently available
method, concentrations of E2 fatty acid esters in lipoproteins are probably too low
to be quantified in nonpregnant subjects. Levels of nonesterified E2 associated
with LDL or LDL+VLDL fractions, however, have been measured by RIA in
nonpregnant subjects, but these studies have yielded conflicting results
(Leszczynski et al. 1987; Santanam et al. 1998). The inconsistency between these
studies may be attributed to the small numbers of subjects, the different
lipoprotein isolation procedures, and the potentially inadequate purification of the
isolated lipoprotein fractions prior to immunoassay.
Biological function of  lipoprotein-associated 17β-estradiol  esters
Our data show similarities with studies of fatty acid esters of DHEA and
pregnenolone, which are also synthesized by LCAT in plasma. DHEA and
pregnenolone fatty acid esters associate mainly with HDL and LDL in both
human (Lavallée et al. 1996b; Roy and Bélanger 1992) and rodent plasma
(Bélanger et al. 1992) and they have been shown to function as substrates for
steroid formation in steroidogenic and peripheral cells, following internalization
via lipoprotein receptors (Roy and Bélanger 1991; Provencher et al. 1992; Roy
and Bélanger 1993). Thus, in theory, incorporation of lipophilic E2 fatty acid
esters in lipoproteins could be another means of estrogen transport to peripheral
cells.
Receptor-mediated uptake of HDL-associated E2 by endothelial cells has
recently been suggested as a new mechanism for the cardiovascular effects of
HDL and estrogen. Gong et al. (2003) showed that HDL-associated E2 induced
vasodilatation by activating endothelial nitric oxide synthase (eNOS) after HDL
binding to its receptor, scavenger receptor class B type I (SR-B1), in endothelial
cells. The stimulation of eNOS in endothelial cells was induced by HDL obtained
from premenopausal women and postmenopausal women receiving estrogen
therapy, but not by HDL from men or postmenopausal women without estrogen
treatment. In the HDL fractions from women and from female mice that
stimulated eNOS, physiologic plasma concentrations of E2 were detected.
However, E2 fatty acid ester levels were not analyzed in that study. From previous
studies, it is known that HDL, and especially HDL3, binds E2 in plasma and
metabolizes it to fatty acid derivatives (Leszczynski and Schafer 1991;
Höckerstedt et al. 2002). Furthermore, our present and previous studies indicate
that most of the HDL-associated E2 is in the form of fatty acid esters (Helisten et
al. 2001). It is not known whether E2 esters might be activated by hydrolysis in
endothelial cells or whether intact E2 ester molecules might be effective.
Another interesting possibility is that, incorporated in lipoproteins, E2 fatty acid
esters might act as antioxidants, protecting lipoproteins against oxidative
modification. E2 17-fatty acid esters in high concentrations (≥ 10 nmol/l) have
been at least as effective as nonesterified E2 in inhibiting either cell-mediated
(Kuohung et al. 2001) or copper mediated oxidation of LDL in vitro (Meng et al.
1999; Abplanalp et al. 2000). Furthermore, Shwaery and coworkers have shown
that incubation of plasma with physiologic concentrations (1 to 100 nmol/l) of
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labeled E2 was followed by incorporation of a lipophilic E2 derivative to LDL and
a subsequent increase in the resistance of LDL to oxidation, as measured by the
formation of conjugated dienes in response to Cu2+ (Shwaery et al. 1997; Shwaery
et al. 1998). DTNB, the LCAT inhibitor, inhibited the association between E2
derivatives and LDL and, subsequently, the antioxidant protection of LDL
(Shwaery et al. 1997). The E2 ester concentrations in pregnancy LDL measured in
the present study, 0.05 to 0.38 pmol/mg LDL protein, were similar to the amounts
of esterified labeled E2 that increased the oxidation resistance of LDL in the
previous study by Shwaery et al. (1997). Thus, elevated levels of LDL-associated
E2 fatty acid esters might potentially contribute to the increased resistance of LDL
to copper-mediated oxidation that has been described in pregnancy (De Vriese et
al. 2001).
6.3. 17β-Estradiol esters in ovarian follicular fluid
We found that ovarian follicular fluid had a high concentration of E2 fatty acid
esters and nonesterified E2, consistent with other studies (Larner et al. 1993;
Cigliano et al. 2001). The proportion of esterified E2 to nonesterified E2 (3% to
10%) was lower in our study than that detected by another study (20% to 165%)
(Larner et al. 1993). This may be attributed to the small study populations and to
the high interfollicular variability in both E2 esters and E2 concentrations in
follicular fluid (Larner et al. 1993). The proportion of esterified E2 to nonesterified
E2 in the present study was, however, in line with the conversion rate of labeled E2
to its fatty acid derivatives reported in follicular fluid incubation studies (5% /24 h
and 7% /96 h) (Pahuja et al. 1995; Roy and Bélanger 1989a).
6.4. The effect of postmenopausal estrogen therapy
on the concentrations of serum 17β-estradiol fatty
acid esters
Oral E2 therapy increased the median levels of serum E2 fatty acid esters in
postmenopausal women by 27% and 29% in Studies III and IV, respectively. The
median concentrations of serum nonesterified E2 increased by approximately nine-
fold during three months’ therapy with oral E2 2 mg/d (Study III) and ten-fold
during one month’s administration of oral E2 valerate 2-4 mg/d (Study IV).
Consistent with our previous results in pregnancy, there was a positive correlation
between serum levels of E2 fatty acid esters and serum nonesterified E2 levels
during oral E2 therapy. In Study IV, the increase in serum E2 esters also correlated
with marked increases in serum E1 and SHBG concentrations that were due to the
high dose of oral E2 and its first pass metabolism in the gut and the liver. In
contrast to oral estrogen therapy, the 50-100 µg/d dose of transdermal E2 did not
induce statistically significant changes in serum E2 fatty acid ester concentrations
in either study. This may be attributed, at least partly, to the lower estrogen dose
of transdermally administered E2 compared with oral E2 administration, as
reflected by only five-fold (Study III) and seven-fold (Study IV) increases in the
median serum E2 concentrations during transdermal E2 administration. In the light
of our previous findings that serum levels of E2 esters correlated with serum
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nonesterified E2 levels (Study I), one would have expected, however, that some
increase in serum E2 ester levels would also have taken place during transdermal
E2 administration. One possible explanation might lie in the different
pharmacokinetics of orally and transdermally administered E2, as transdermal E2
treatment lacks the high peak serum E2 values of oral estrogen treatment that
might enhance esterification of E2 in plasma. Thus, the route of estrogen
administration may play a role in the formation of esterified E2 during
postmenopausal estrogen therapy. However, the number of subjects in these
studies was limited, and thus, the effect of transdermal E2 treatment on serum E2
ester levels might not have been detected. It is also possible that the effect of
transdermal E2 treatment on serum E2 ester levels would emerge only after a
longer period of time, as is the case with the effects of transdermal estrogen
therapy on serum lipid levels (Ory et al. 1998).
Because circulating E2 fatty acid esters are apparently synthesized and
associated with lipoprotein particles in the blood, the potential relationship
between E2 esters and serum lipid levels was also studied. However, none of the
changes in lipoprotein cholesterol (Study IV) or lipoprotein phospholipid or
triglyceride content or apolipoprotein levels (Study III) correlated with changes in
E2 fatty acid ester concentrations during estrogen therapy. These data suggest that
circulating E2 concentrations are more important than HDL levels in determining
serum E2 fatty acid ester concentrations.
The findings in Study IV were consistent with the observations made in Study
III, and its crossover design added to the reliability of the results. The
concentrations of serum E2 fatty acid esters measured in Study IV were slightly
lower than those obtained in Study III. This variability in E2 ester levels between
the two studies may be attributed to the relatively small study populations. In
Study III, the proportion of serum E2 fatty acid esters to serum E2 in seven young
premenopausal women was in the range of 9% to 55%. Our data are supported by
the study of Larner et al. (1992b), who reported that the proportion of E2 fatty acid
esters to E2 in four premenopausal women was in the range of 1% to 22%, and if
recalculated without subtracting the male serum value, approximately 6% to 38%.
In that same study, however, serum E2 ester levels were considered not to be
detectable in postmenopausal women (Larner et al. 1992b). Methodological
differences and determination of the detection limit could explain this discrepancy
between their data and ours, as, in contrast to us, they subtracted the value
measured in human male serum from the E2 ester values in female serum samples.
In the postmenopausal women in Studies III and IV, the baseline ratios of
serum E2 ester to nonesterified E2 were unexpectedly high, in fact, there was more
esterified E2 than nonesterified E2. This was surprising, and led to speculations
about the source of the fatty acid esterified E2 in postmenopausal women. If
synthesized in the blood by LCAT, the substrate E2 must be produced by
peripheral aromatization of androgens of gonadal and adrenal origin. But how
could the markedly increased esterification of E2 during the menopause be
explained? Studies by us and by others suggest that the proportion of esterified E2
to E2 may be higher when the levels of E2 are lower. We observed that the serum
E2 ester to E2 ratio in pregnancy was inversely correlated with the serum E2 levels.
In line with this observation, others have shown that a higher E2 ester to E2 ratio
was associated with lower E2 levels in follicular fluid in which E2 was similarly
esterified by LCAT (Cigliano et al. 2001). Aging has also been attributed to
increased formation of E2 fatty acid esters. In aging cultured myometrial cells, E2
metabolism was shown to switch from predominance of oxidation to E1 to an
increase in E2 fatty acid ester formation (Vallet-Strouve et al. 1986). Also, studies
in aging men and women have suggested that the formation of fatty acid esters of
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another steroid, DHEA, increases specifically in the serum between 20-40 and 70-
80 years of age (Bélanger et al. 1994; Labrie et al. 1997b). The lipophilic E2 fatty
acid esters are long-lived hormones, and thus, E2 fatty acid esters may serve as a
storage form of estrogen during estrogen depletion (Hochberg 1998). In
agreement with this hypothesis, high levels of E2 fatty acid esters have been
detected in subcutaneous and omental adipose tissue in women as much as 15-20
years after the menopause (Larner et al. 1992b). The role of E2 fatty acid esters as
a storage form of active E2 is further supported by metabolic studies. The plasma
half-life of E2-17-stearate is longer that that of free E2 and, more importantly, its
metabolic clearance rate is almost nine times lower than that of E2 (Larner and
Hochberg 1985). Radiometric studies in men indicate that E2 esters are removed
from the circulation into the tissues, where their oxidative metabolism continues
more extensively and much more slowly compared with the parent steroid E2
(Hershcopf et al. 1985). This may be attributed to the slow hydrolysis of E2 esters
by tissue esterases.
Effect  of previous intrahepatic cholestasis of  pregnancy on the fatty
acid esterification of 17β-estradiol
In study IV, the effect of postmenopausal E2 therapy on serum E2 esters was
compared between women with a history of intrahepatic cholestasis of pregnancy
(ICP) and healthy postmenopausal control women. Estrogen metabolism has been
shown to be altered in ICP because of the impaired enterohepatic circulation
(Adlercreutz et al. 1974), and estrogen treatment has provoked signs of cholestasis
in women with a history of ICP (Drill 1974). Therefore, it was hypothesized that
esterification of E2 might be impaired during estrogen treatment in women with
previous ICP. No significant differences in esterification of E2 were observed
between these two groups during the study. However, after oral estrogen
treatment, the plasma activities of the hepatic enzymes ALAT, ASAT, and γ-GT
were slightly higher in the ICP group than in the control group but mostly
remained within the normal range. This is in agreement with previous studies, in
which oral estrogen administration has either had no effect on serum
transaminases or has increased their activities only transiently in women with a
history of ICP (Jeppsson and Rannevik 1976; Jeppsson et al. 1973).
Implications of increased concentrations of serum 17β-estradiol
fatty acid esters in postmenopausal women
The clinical consequences of increased serum E2 fatty acid ester levels in
postmenopausal women receiving oral estrogen therapy are not known. Because
of their slow metabolism, they might accumulate in tissues of women receiving
oral estrogen therapy. To what extent E2 fatty acid esters contribute to the
estrogenic effects of oral estrogen replacement therapy remains, however,
unknown.
An increased serum E2 fatty acid ester level and thereby an increased amount of
esterified E2 associated with LDL could, in theory, contribute to the decreased
susceptibility of LDL to oxidative modification during oral estrogen therapy
observed in several studies (Wilcox et al. 1997; Wakatsuki et al. 1998; Özden et
al. 2001). However, studies on the effects of oral estrogen therapy on LDL
resistance to oxidation have not yielded consistent results, and, furthermore,
transdermal estrogen administration has also been reported to inhibit the oxidative
modification of LDL in vitro (Sack et al. 1994; Koh et al. 1997; Wakatsuki et al.
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2002). Therefore, more studies are needed to clarify the possible role of E2 fatty
acid esters acting as antioxidants incorporated in LDL and HDL.
An interesting observation in Study III was the positive correlation between the
change in serum E2 fatty acid ester levels and the change in forearm blood flow
responses during three months of oral and transdermal E2 and placebo treatment.
This correlation was statistically significant between measures of both
endothelium-dependent and -independent vasodilatation and serum E2 esters. In
contrast, no significant correlation has been observed between serum nonesterified
E2 levels and endothelial function, even though oral E2 therapy had significantly
improved blood flow responses in the women studied (Vehkavaara et al. 2000).
The recent observation by Gong et al. (2003) that HDL-associated endogenous
estrogen induced stimulation of eNOS and vasodilatation is particularly
interesting, and suggests a mechanism whereby HDL-associated esterified E2
could mediate vasodilatory effects during postmenopausal estrogen therapy.
However, other metabolic changes induced by oral E2 therapy, such as an increase
in HDL cholesterol and decreases in LDL cholesterol and serum testosterone
concentrations, are also likely to contribute to the improvement in endothelial
function during oral E2 therapy (Vehkavaara et al. 2000).
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7. Summary and conclusions
The results of Studies I to IV can be summarized as follows:
1) A reproducible method was developed for the quantitative determination of
serum E2 fatty acid esters. In pregnancy, only a small fraction of the serum total
E2 was in the fatty acid esterified form. Pregnancy serum E2 ester levels correlated
positively with serum E2 levels, although the proportion of serum E2 esters to E2
appeared to decrease during advancing pregnancy. Consistent with previous
studies, ovarian follicular fluid contained substantial amounts of fatty acid
esterified E2.
2) The concentration and distribution of E2 fatty acid esters in human lipoproteins
were determined for the first time. Most of the circulating E2 fatty acid esters in
pregnancy serum were associated with lipoproteins. The principal transporter of
esterified E2 was HDL. This study supports the previous experimental data of E2
esterification in HDL3 particles and the subsequent transfer of E2 esters to LDL.
Suggested biological functions for lipoprotein-associated E2 esters include
transport and receptor-mediated uptake by target tissues, as well as antioxidant
action.
3) In a randomized, placebo-controlled study, oral E2 therapy increased serum
levels of E2 fatty acid esters statistically significantly in postmenopausal women.
In contrast, transdermal E2 therapy had no significant effect on circulating E2 ester
concentrations. The change in serum E2 ester concentration during treatment was
positively correlated with the changes in both endothelium-dependent and -
independent vasodilatation. The study thus raises the possibility that E2  fatty acid
esters might contribute to the beneficial effects of oral E2 therapy on vascular
function in postmenopausal women.
4) A history of intrahepatic cholestasis of pregnancy did not affect the
esterification of E2 during postmenopausal estrogen therapy. The median
concentrations of serum E2 esters increased both in women with a history of ICP
and in healthy postmenopausal control women during oral estrogen treatment, but
no significant changes in serum E2 esters were observed during transdermal
estrogen administration. The results indicate that the effect of oral estrogen
therapy on serum E2 ester concentration is dependent on the higher estrogen dose
during oral as compared with transdermal E2 administration, and, possibly, on the
route of administration.
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